

Concordant inter-laboratory derived concentrations of ceramides in human plasma reference materials via authentic standards

Received: 26 November 2023

Accepted: 27 August 2024

Published online: 03 October 2024

 Check for updates

A list of authors and their affiliations appears at the end of the paper

In this community effort, we compare measurements between 34 laboratories from 19 countries, utilizing mixtures of labelled authentic synthetic standards, to quantify by mass spectrometry four clinically used ceramide species in the NIST (National Institute of Standards and Technology) human blood plasma Standard Reference Material (SRM) 1950, as well as a set of candidate plasma reference materials (RM 8231). Participants either utilized a provided validated method and/or their method of choice. Mean concentration values, and intra- and inter-laboratory coefficients of variation (CV) were calculated using single-point and multi-point calibrations, respectively. These results are the most precise (intra-laboratory CVs $\leq 4.2\%$) and concordant (inter-laboratory CVs $< 14\%$) community-derived absolute concentration values reported to date for four clinically used ceramides in the commonly analyzed SRM 1950. We demonstrate that calibration using authentic labelled standards dramatically reduces data variability. Furthermore, we show how the use of shared RM can correct systematic quantitative biases and help in harmonizing lipidomics. Collectively, the results from the present study provide a significant knowledge base for translation of lipidomic technologies to future clinical applications that might require the determination of reference intervals (RIs) in various human populations or might need to estimate reference change values (RCV), when analytical variability is a key factor for recall during multiple testing of individuals.

Mass spectrometry (MS) is a powerful technology that allows the qualitative and quantitative analysis of circulating metabolites, including lipids, in blood plasma¹. Challenges in the translation of MS-based analytical methods stem from technical aspects (e.g., dependency on stringent and consistent sampling procedures, reproducibility between different laboratories, control of bias and noise)^{2–4}. Beyond that, introducing and adopting new MS-based workflows into existing fields will require additional efforts, such as demonstrating cost-benefit effectiveness, scale, and pertinent turn-around times from

sampling to reporting. In the case of clinical applications, demonstration of utility to individuals and populations will be required in addition to economic benefit⁵.

Once established, through future efforts by the scientific community, reference intervals (RI, aka reference ranges) will be an important tool for the convincing communication of lipidomic measurements and clinical adoption of laboratory-developed tests (LDT) within established clinical practices. RI represent lower and higher concentration boundaries of analytes, lipids, and metabolites, in the

✉ e-mail: kim@lipidomicsconsulting.com; robert.ahrends@univie.ac.at; mwenk@hbku.edu.qa

case of lipidomics and metabolomics, respectively. Clinicians use and rely on established RI for interpretation of laboratory results, medical diagnosis, and evaluation of treatment options for patients within a given reference group (e.g., total cholesterol, LDL-cholesterol RI according to different sex, age, and ethnicity). Appropriate standardization, which is the focus of this manuscript, is a pre-requisite for (i) establishment and (ii) transportability of RI.

This inter-laboratory and cross-platform study is an extension of a community-initiated effort that started in 2017 and is now hosted by the International Lipidomics Society. As detailed and recommended in the initial proposal, reporting of molar concentrations of individual lipids by different laboratories should be regarded as a first step in harmonizing plasma lipidomics. The main goals of this study were to: (i) evaluate the degree of accuracy and concordance obtained in a large inter-laboratory trial using the same shared samples and custom-tailored calibrant materials; (ii) highlight technical issues contributing to variability and technical outliers to avoid in future; (iii) document as precisely as possible the absolute concentrations of four circulating lipids in a publicly available standard reference material and (iv) lay the foundation for determination of MS-based lipidomic RI in diverse human populations across the world in a standardized fashion.

The evaluation of utility of population RIs for the interpretation of lipidomic results is an important step that needs evaluation. If the analyte shows low individuality and the value dispersion in each individual covers most of the dispersion among individuals, then the RI value is a useful parameter⁶. However, for analytes showing high individuality the use of RI is not recommended, while monitoring longitudinal changes of concentrations by the reference change values (RCV) application is a better strategy. The RCV is defined as the change needed between two serial results from the same individual to be statistically significantly different⁷. The RIs are descriptive of a specific population, derived from a reference distribution (usually 95% interval) and are different from the decision limits above or below which a specific medical decision is recommended. And because we must consider that, for many analytes, a continuous variation may have diagnostic significance, the concept of RCV is useful, although not much used in everyday practice.

Why ceramides? The initial group of investigators involved in the human blood plasma guidelines initiative⁸ identified ceramides, among other circulating lipids, as a particularly well-suited test case for a number of reasons including: (i) *Disease association*: Ceramides are associated with major adverse cardiovascular events in individuals with coronary artery disease, Type 2 Diabetes, renal impairment, and age^{9–13} as well as major depressive disorders¹⁴. (ii) *Clinical utility*: Ceramides are used clinically to identify the risk of adverse cardiovascular events within 5 years^{15,16}. (iii) *Actionability*: Circulating ceramide levels can be modified by long-term lifestyle interventions^{17–19}, and the sphingolipid synthetic pathway can be targeted therapeutically (e.g. via several naturally occurring enzyme inhibitors and derivatives thereof such as Fingolimod)^{20,21}. (iv) *Genetic heritability*: Ceramides display among the highest reported heritability values of blood lipids in different populations, and accordingly, sphingolipids are strongly influenced by ethnicity²². (v) *Technical considerations*: Analyte stability, detectable concentration levels in the circulation with currently used analytical platforms, and availability of standards were additional important considerations.

Results

The main goal of this community effort was to compare MS measurements between a large number of laboratories ($n = 34$) using the (i) same human blood plasma reference materials (four NIST plasma RMs)²³, utilizing (ii) the same synthetic standards (a mixture of deuterated ceramides at a pre-defined concentration prepared by Avanti Polar Lipids), and (iii) to report absolute concentrations of four

ceramide species (Cer 18:1;O2/16:0, Cer 18:1;O2/18:0, Cer 18:1;O2/24:0 and Cer 18:1;O2/24:1) in the different RMs.

The choice of the NIST SRM 1950 as one of the RMs was deliberate given its commercial accessibility offering widespread access and utility. Consequently, this material has been used in numerous lipidomic and metabolomic community-driven studies^{24–29}. Furthermore, NIST SRM 1950 is a relatively well-characterized standard reference material (e.g., sterol and fatty acid concentrations are certified by NIST). It is increasingly being adopted in the lipidomic and metabolomic communities for inter-laboratory comparisons and as a shared reference material for human plasma studies^{30–32}. The other three RMs²³ used in this ring trial allowed us to test different matrix effects which might be useful in future clinical research³³. As ceramides are implicated in cardio-metabolic diseases, we included pooled samples from populations with hypertriglyceridemia (hTAG) and diabetes (DB), respectively. Ethnicity is another factor affecting plasma sphingolipid levels³⁴. For this reason, we also analysed the Young African American (YAA) blood plasma as one of the RMs.

To help standardize experimental steps between laboratories experienced in lipidomic analysis and those newer to this field, a “Standard” operating protocol (referred to as SOP throughout, see Supplementary Information) was prepared by the study coordinators, according to a published quantitative method³⁵. This SOP included detailed, step-by-step procedures covering ceramide extraction from human blood plasma, preparation of external calibration curves using deuterated and non-deuterated synthetic standards, and use of MRM-based LC-MS/MS for measurement on triple quadrupole instruments. A template to design the sample analytical sequence and data reporting in a standardized format was also included (see the SOP in Supplementary Information). To minimize variability-associated procedures, peak areas were chosen as the raw data report format rather than concentration values derived by normalization to internal standards. The structured data reports facilitated integration with a specially designed pipeline for automated downstream processing, including conversion of peak areas to concentration values. The pipeline was designed to simplify reproducibility of both tabular and graphical results. The structured reporting format contained sections to report peak areas for all four ceramides and their labelled counterparts in columns, with three replicates each. The report rows contained the peak areas of all dilution steps of both calibration line samples for multi-point calibration, the areas for every aliquot of each RM, the areas for each concentration step of the QC samples, and finally for the ceramide peak areas measured in the matrix and total blank samples (see the SOP in the Supplementary Information for the definitions of different sample types). The calibration lines were calculated using R’s ‘lm’ method, regressing the ceramide area to labelled standard ratio on the known concentration, weighted by $1/x^2$, following the method used by Kauhanen et al.³⁵. We then evaluated the average of the calibration lines for each lab to calculate the adjusted concentrations from the reported areas of each ceramide and corresponding labelled standard within the QC and RM samples (Supplementary Fig. 1). As a commonly adopted procedure in lipidomics, the concentration was also calculated using a single-point calibration, based on the ratio of each ceramide and its corresponding labelled standard, multiplied by the known internal standard concentration. The individual concentrations were then combined and enriched with lab-specific metadata, e.g., the methodology and MS-platform used, to calculate CV values for the inter-lab comparison.

The participating laboratories were also invited to use their preferred protocol (from extraction to detection to the type of instrument used) with which they might be more familiar, either as an alternative or an addition to the SOP (referred to as OTHER below). However, the same set of synthetic standards were to be used in either case. At the end of the study, we collected 23 datasets generated with the SOP method and 15 with OTHER methods. The latter included a

Table 1 | Analytical methods and platforms

Method	SOP	OTHER		
MS platform	QQQ/QTRAP	QQQ/QTRAP	QTOF	Orbitrap
Number Datasets	23 (23 RP)	10 (8 RP, 2 FIA)	3 (2 RP, 1 SFC)	3 (2 RP, 1 FIA)
Sum	23	16		

SOP refers to the method recommended by the study authors, OTHER to methods chosen by the individual laboratories. The number in brackets indicates the number for each chromatographic/injection method (RP Reversed Phase, FIA Flow Injection Analysis, SFC Supercritical Fluid Chromatography). Other variations present in OTHER may include type of extraction, nano/capLC, LC duration (7–50 min), column chemistries and MS source settings. Platforms: QQQ = triple quadrupole, QTRAP = ion trap, QTOF = quadrupole time-of-flight.

combination of different techniques, such as nano or capillary-LC, flow injection analysis (FIA), different types of LC columns and gradients, as well as different detection methods (Table 1). The breadth of different approaches allowed us to observe the influence of a prescribed methodological procedure (SOP) in comparison to performing the measurements in different ways (OTHER) and, importantly, the effect that a common set of carefully adjusted standards might have on the quantitation performances when different methodologies are used. All the final annotated data are available as Supplementary Data.

It should be noted that for simplicity, since all four ceramides share the same sphingoid base moiety, i.e., 18:1;O2, we will refer to Cer 18:1;O2/16:0 as Cer16, Cer 18:1;O2/18:0 as Cer18, Cer 18:1;O2/24:0 as Cer24:0, and Cer 18:1;O2/24:1 as Cer24:1 in the text, but always according to the updated LIPID MAPS nomenclature in the displays and tables³⁶. In addition, and again for simplicity, we limit the report of the results in the next section to those obtained for NIST SRM 1950 plasma. A separate paragraph will discuss the comparison of ceramide concentrations between the four RMs.

Before estimating consensus values for the concentration of the ceramides in SRM 1950, we analysed the data contributed by all the participant laboratories (Fig. 1). This allowed us to compare the reproducibility of the results between different methods and instruments, starting from the same plasma sample and internal standard mixtures and excluding possible effects derived from different ways of estimating concentration values. Please note that the results shown in Fig. 1 and Supplementary Fig. 2 represent the full dataset, with outlier removal thresholds based on Tukey's $1.5 \times \text{IQR}$ fences³⁷ represented and determined separately for each of the four ceramides and quantification methods, i.e., single vs. multi-point calibration. The outliers filtering resulted in the exclusion of 4 (10% of the total contributions) for Cer16 and Cer24, and 8 sets (21%) for Cer18 and Cer24:1, respectively, when considering multi-point calibration (Supplementary Table 1 and Supplementary Data). Outliers were not represented in Figs. 2 and 3 and in specific Supplementary Figs. (please refer to the corresponding legends).

The medians of the intra-lab CVs ranged from 3.7 to 4.2% for the concentration of the four ceramides when using the multi-point calibration, confirming good reproducibility between the measurements acquired by the individual participants (Fig. 1, Table 2). The level of concordance of the measurements between the different contributors was estimated by the inter-lab CVs, ranging from 9 % to 14% when excluding outliers, and 25% to 31% for the unfiltered dataset (Table 2 and Supplementary Table 1). The concordance of the results between the participants was not affected by the use of SOP or OTHER procedures, as the values generated from these two groups were not significantly different ($P > 0.05$) for any of the analytes in all RMs (Supplementary Table 2 and Fig. 1). Considering the disparity between the number of contributions obtained with low (quadrupole/linear ion traps, $n = 33$) and high resolution (Orbitrap and Time of flight, $n = 6$, Table 1) instruments, we are not reporting any statistics for this comparison, although we did not find

significant differences between these two sets of results. In addition, the CV did not show any obvious dependency on the signal intensity of the measured molecules, except for measurements acquired via FIA, where the sensitivity of the detection was lower for low abundant ceramides (e.g., Cer18 in Fig. 1, Lab #22). Collectively, these results demonstrate that precise and concordant (low intra- and inter-lab CVs, respectively) values can be obtained independently of different methods and MS platforms in many laboratories and establish the concentrations based on calibration curve quantification for the four ceramides in SRM 1950 as $0.244 \pm 0.006 \mu\text{mol/L}$ for Cer 18:1;O2/16:0 (mean $\pm$ SEM; $n = 35$), $0.0835 \pm 0.0017 \mu\text{mol/L}$ for Cer 18:1;O2/18:0 ($n = 31$), $2.42 \pm 0.04 \mu\text{mol/L}$ for Cer 18:1;O2/24:0 ($n = 35$) and $0.855 \pm 0.013 \mu\text{mol/L}$ Cer 18:1;O2/24:1 ($n = 31$) (Table 1).

Estimation of ceramides concentrations in SRM 1950 by single-point internal standard vs. multi-point calibration curve

To generate reference values and absolute concentrations for the four ceramides in SRM 1950 plasma, we chose to quantify the analytes in two different ways, namely (i) via the use of calibration curves (multi-point, Fig. 1 and Supplementary Fig. 1) and (ii) by using the labelled internal standards (single-point calibration in a verified linear range, Supplementary Fig. 2). While the second approach is common when performing large lipidomic studies utilizing a small set of internal standards representative of each of the lipid classes measured and their concentrations, the use of a calibration curve built with both endogenous and labelled molecules is characteristic of targeted approaches. It should aid in accurate quantitation, minimizing the errors that could occur when using a single-point calibration. As both methods are currently part of lipidomic workflows, we tried to clarify if, in this specific case, a significant benefit was conferred by either of them. As previously mentioned, we used only the dataset without outliers for this comparison. This exercise aimed to estimate if the two procedures generate the same results with the same variability between laboratories. When considering all the participating laboratories independently of the analytical method used (SOP vs. OTHER methods), we obtained inter-lab CVs for concentrations derived using single-point normalization of 9.2% for Cer16:0, 9.8% for Cer18:0, 11.4% for Cer24:0, and 14.9% for Cer24:1, respectively, while the corresponding CVs for concentrations derived using the multi-point calibration (external calibration curve) were 13.8%, 11.6%, 10.1% and 8.5% (Table 2).

When comparing the mean absolute concentrations determined via single- or multi-point calibration, we observed different values for Cer16 and Cer18, but not Cer24:0 and Cer24:1 (Fig. 2, Table 2). In the case of Cer16 we note a 1.4-fold higher concentration (for single-point) when compared with the multi-point calibration results. The opposite is true for Cer18. We do not have a conclusive explanation for this discrepancy other than a possible disagreement in amount between labelled and unlabelled standards in the case of Cer16 and Cer18, also observed in the calibration curves prepared in bovine serum albumin solution (Supplementary Fig. 1). Given the excellent agreement between single-point and multi-point quantifications in the case of Cer24:0 and Cer24:1, it can be argued that the absolute levels of endogenous Cer24:0 and Cer24:1 in NIST SRM 1950 are close to 2.48 and $0.85 \mu\text{mol/L}$ (average of single-point and multi-point calibration), respectively, unless both unlabelled and labelled ceramide standards employed for calibration were affected by the same concentration bias.

Inter-laboratory CVs of SOP-based results were marginally lower than those obtained by OTHER methods, collectively confirming that appropriately titrated authentic labelled standards significantly reduce variability, irrespective of the degree of standardization of the procedures.

Comparison of ceramides levels in different reference materials

The concentration values of the four ceramides were obtained for each of the RMs (i.e., SRM 1950 and the three materials within RM 8231) with




Fig. 1 | Consensus concentrations of ceramides in NIST SRM 1950 across all study participants. Concentrations of the 4 reported ceramides in NIST SRM 1950. Each circle corresponds to the mean of 1 to 6 replicate measurements from a vial of NIST SRM 1950 shipped to each of the participating laboratories. The error bars depict the $\pm 1 \times \text{SD}$ of 3 injection replicates, which in some cases is smaller than the diameter of the plotted circle or absent if only 1 measurement was made. Horizontal bars represent the mean values of the mean measured concentration

per NIST vial. The outer green dotted lines indicate used for as cut-off values for outlier removal. The mean $\pm 2 \times \text{SD}$ (dashed grey lines) are based on data after outlier removal. Molar concentrations were calculated using the external calibration curve (multi-point calibration). SOP (red) and OTHER (blue) refer to the Standard vs Other methods, respectively. Source data are provided as Source Data File.




Fig. 2 | Comparison of single-point and multi-point calibrations. Molar concentrations derived from single-point vs. multi-point calibration based quantifications. The diagonal line indicates equal results between single-point (horizontal axis) and multi-point (vertical axis) calibration-based quantification. Outlier measurements were removed for each ceramide species in each reference plasma (see

Fig. 1 and text). Each circle corresponds to the mean value reported by one laboratory ($n = 6$). NIST SRM 1950 (SRM, dark blue); hypertriglyceridemic (hTAG, red), diabetic (DB, light orange), and Young African American (YAA, light blue), which are part of NIST RM 8231. Source data are provided as Source Data File.




Fig. 3 | Concentration values of ceramides in NIST SRM 1950 and the suite of human plasma RM contained in RM 8231. Concentrations of the 4 ceramides in different NIST reference plasma samples. Each circle corresponds to the values reported by one laboratory. P values are based on paired two-tailed t -tests of complete datasets. The horizontal bars correspond to the mean $\pm 1 \times$ SD of all

shown data per group (number of data points indicated below each group). Outlier measurements were removed for ceramide species in each reference plasma (see Fig. 1 and text). SOP (red) and OTHER (blue) refer to the Standard vs Other methods, respectively. Source data are provided as Source Data File.

the two different procedures described above. Also here, we removed outliers for each RM and ceramide species, using the Tukey's $1.5 \times \text{IQR}$ approach as previously described. As expected, the values generated by single-point and multi-point calibration for Cer24:0 and Cer24:1 fall along the $y = x$ line of equality (5% lower and 3% higher, respectively, when using multi-point compared to single-point calibration), while Cer16 and Cer18 show a clear bias away from the $y = x$ line, with 30.1% lower and 51.5% higher values, respectively (Fig. 2 and Table 2). The mean concentrations of all ceramide species were elevated in the RM 8231-2 (hypertriglyceridemic, hTAG) when compared with SRM 1950, most strikingly for Cer24:0 and Cer24:1 (1.56 fold and 1.47 fold, respectively) confirming previous results of 1.5-2 fold changes from the same comparison using different MS-platforms^{23,33}. These results are consistent with many independent human plasma lipidomic studies that reported a positive correlation between TAG and ceramides.

Genetic and environmental conditions such as diet and exercise influence circulating sphingolipids, including ceramides. Ceramides

display high genetic variability compared to other circulating lipids^{38,39} and vary across different ethnicities, age and sex⁴⁰. The levels of all four ceramide species are significantly lower in RM 8231-3 (Young African American, YAA, Fig. 3, Supplementary Table 1), again in agreement with previous characterizations of these RM^{23,33}, thus calling for determination of stratified reference intervals for applications in clinical testing. The concentrations of all four ceramides in the diabetic RM (RM 8231-1) were not significantly different from SRM 1950, consistent with previous studies^{23,33}. We did not observe any consistent difference in inter-lab variation of concentration values between the four RM (Fig. 3, Table 2 and Supplementary Table 1). This suggests that the measurements had comparable concordance among the laboratories for different matrices, despite their potentially different properties, e.g., the hTAG plasma sample being of different viscosity and YAA having lower ceramide concentrations, compared to SRM 1950.

Table 2 | Consensus concentrations of the 4 measured ceramides in the 4 NIST reference materials

Matrix	Ceramide	<i>n</i> (SP) (SOP/OTH)	<i>n</i> (MP) (SOP/OTH)	μmol/L (SP) mean	μmol/L (SP) SEM	μmol/L (MP) mean	μmol/L (MP) SEM	Inter-lab %CV (SP)	Inter-lab %CV (MP)	Intra-lab %CV (MP)
SRM	Cer 18:1;O2/16:0	33 (21/12)	35 (21/14)	0.3507	0.0056	0.2438	0.0057	9.2	13.8	4.2
	Cer 18:1;O2/18:0	33 (22/11)	31 (21/10)	0.0553	0.0009	0.0835	0.0017	9.8	11.6	4.2
	Cer 18:1;O2/24:0	35 (20/15)	35 (20/15)	2.5670	0.0494	2.4116	0.0413	11.4	10.1	3.7
	Cer 18:1;O2/24:1	32 (21/11)	31 (20/11)	0.8397	0.0221	0.8554	0.0130	14.9	8.5	3.7
hTAG	Cer 18:1;O2/16:0	35 (22/13)	35 (20/15)	0.4019	0.0086	0.2888	0.0062	12.7	12.8	5.8
	Cer 18:1;O2/18:0	34 (22/12)	31 (20/11)	0.0652	0.0015	0.0995	0.0020	13.5	11.0	5.6
	Cer 18:1;O2/24:0	35 (20/15)	36 (21/15)	3.9250	0.0892	3.7641	0.0765	13.4	12.2	4.2
	Cer 18:1;O2/24:1	34 (21/13)	33 (20/13)	1.2207	0.0400	1.2784	0.0267	19.1	12.0	4.7
DB	Cer 18:1;O2/16:0	33 (22/11)	35 (21/14)	0.3088	0.0060	0.2161	0.0052	11.2	14.3	5.5
	Cer 18:1;O2/18:0	35 (22/13)	32 (21/11)	0.0631	0.0014	0.0966	0.0020	13.3	11.8	5.0
	Cer 18:1;O2/24:0	35 (20/15)	36 (21/15)	2.5252	0.0498	2.4013	0.0475	11.7	11.9	3.5
	Cer 18:1;O2/24:1	35 (21/14)	33 (21/12)	0.8498	0.0308	0.8663	0.0173	21.4	11.5	4.4
YAA	Cer 18:1;O2/16:0	34 (21/13)	34 (20/14)	0.2127	0.0048	0.1450	0.0039	13.1	15.6	6.3
	Cer 18:1;O2/18:0	33 (22/11)	34 (21/13)	0.0331	0.0007	0.0494	0.0016	12.7	18.6	5.6
	Cer 18:1;O2/24:0	34 (20/14)	35 (21/14)	1.7312	0.0318	1.6485	0.0375	10.7	13.4	3.5
	Cer 18:1;O2/24:1	33 (21/12)	33 (21/12)	0.5333	0.0181	0.5518	0.0135	19.5	14.0	4.6

SOP and OTH refer to the standard and OTHER methods, respectively. *n* indicates the number of datasets that were included in the calculation of the variables given in this table after removal of outliers of the single-point (SP) or multi-point (MP) calibration, respectively, using Tukey's 1.5 × IQR method (see text). The total number of datasets before removal was 39 (26 SOP/13 OTHER). Intra-lab %CV corresponds to the median of individual intra-lab %CVs.




Fig. 4 | Comparison of concentration values obtained in this and previous studies covering ceramides by MS-platforms in NIST SRM 1950. Comparison of inter-laboratory and/or cross-platform trials reporting ceramide concentrations in NIST SRM 1950. Each open circle corresponds to the reported value from one laboratory in each of the respective studies referenced by first author and year of publication. (sp) refers to a single, standardized protocol and platform employed by all laboratories while (mp) denotes studies in which multiple protocols and platforms were used. The red boxes and numbers indicate median ±MAD (mean

absolute deviation) and the number of participating laboratories, respectively. Depending on the precise nature of the study and/or reporting laboratory, concentrations were either reported with sphingoid-base and fatty acyl chain details (e.g. Cer 18:1;O2/16:0) or as sum compositions (i.e. Cer 34:1;O2). In the latter case, isobaric ceramide species other than the 4 ceramides targeted in this study may therefore have contributed to the reported concentrations. Details of the individual studies are presented in Supplementary Table 3. No outlier removal has been applied for any of the studies. Source data are provided as Source Data File.

Comparison with previous inter-laboratory and/or cross MS-platform studies measuring ceramides in NIST SRM 1950

We next compared our results to previous inter-laboratory studies using MS platforms which reported concentration values of ceramides in NIST SRM 1950^{24,27,29,33}. A summary of the comparison is presented in Fig. 4. Note that in this figure we included all datasets from our study, i.e., no outliers were removed, as in other published datasets. Details of the previous trials and this current study are tabulated in Supplementary Table 3, i.e., year of publication, usage of internal standards, type of extraction and MS-platforms, and the number of participating laboratories. As we only measured four endogenous molecules, the most distinguishing feature of our study is the use of authentic labelled

standards for each of the quantified analytes. Furthermore, the choice of extraction protocol and MS platforms in our study were at the discretion of the participants compared with previous trials, with the notable exception of reference²⁴. The current study is also the largest based on the number of participating laboratories and returned datasets. We would also like to highlight and acknowledge that several laboratories participated in more than one of these trials, underlying the broad common efforts put forward by our communities to advance the field through improvement and harmonization of procedures.

We compared the ceramide concentration values and their variability across the five studies wherever possible. For example, the distinct cores within the original LIPID MAPS consortium reported

results in a lipid class-specific fashion, thus limiting the laboratory reporting sphingolipids/ceramides to $n=1$, without an option to calculate inter-laboratory CVs²⁷. Another complicating factor in the comparison of diverse studies is the precise identity of the reported analytes. For example, three out of the five studies reported to the levels of lipid species identities (i.e., Cer 18:1;O2/16:0) while others were based on sum composition (e.g., Cer 34:1;O2) due to technological limitations. Finally, the mean absolute deviations (MAD) in our study are among the smallest despite the large number of participants and diverse methods and MS platforms utilized to generate the results.

Use of authentic vs. class-specific internal standards for calibration

The inclusion of authentic labelled standards, prepared to approximate the levels of endogenous ceramides in human plasma (Supplementary Fig. 1), was an early design choice of our trial. It is grounded in the belief that appropriately matching each analyte with its closest stable-isotope derivative would overcome complications, such as different extraction efficiencies, ionization and fragmentation properties, chain-length dependencies, lack of co-elution in reversed-phase LC. To evaluate the relevance of this choice, we normalized the peak areas returned for each endogenous ceramide species (from each participant laboratory) with either the authentic standard (i.e., the corresponding stable isotope derivative) or one of the other three available labelled standards with differing fatty acid moieties (Fig. 5). For this analysis we excluded the outlier datasets (based on authentic internal standard) as described before (Fig. 1). In the case of the endogenous concentrations of Cer24:0 we obtained $2.41 \pm 0.24 \mu\text{mol/L}$ (mean $\pm$ SD) when using the authentic internal standard for normalization, i.e., D7-Cer24:0, and $3.07 \pm 1.86 \mu\text{mol/L}$ when normalizing with the D7-Cer16

internal standard, corresponding to a 1.27-fold difference in absolute concentrations. In addition, and importantly, the corresponding variabilities were also significantly affected by the choice of the IS and resulted in inter-lab CVs of 10% and 61%, respectively, when using the authentic labelled analyte or not. Similar disparities were found in other permutations of this procedure when testing the use of different labelled standards (Supplementary Fig. 6).

Recalibration of RMs using SRM 1950 as shared reference

The use of shared reference samples can correct systematic method-specific quantitative biases and help in harmonising lipidomic data^{30,31}. Harmonization with shared materials is quite accepted in clinical settings, where accurate results over time and location are achieved by standardising measurements and establishing traceability to a reference system^{41–45}. Since NIST SRM 1950 is commercially available and one of the most popular references for human plasma, we harmonised the data between all participants by using the following procedure: the four ceramides concentration values obtained from the different RMs (hTAG, DB and YAA) by each participating laboratory were normalised by the mean concentration of the corresponding ceramide obtained by the same lab for SRM 1950, according to the following formula (i).

$$c_{\text{Sample } k}^{\text{Analyte } i, \text{Lab } j} (\text{recalibrated}) = \frac{c_{\text{Sample } k}^{\text{Analyte } i, \text{Lab } j}}{c_{\text{SRM1950}}^{\text{Analyte } i, \text{Lab } j}} * c(\text{Ref SRM1950})^{\text{Analyte } i} \quad (\text{i})$$

where the sample's measured concentration is divided by the mean concentration of SRM 1950 replicates measured by the corresponding lab. This unitless ratio is rescaled by multiplying by the concentration assigned to the SRM1950, which corresponds to the consensus value established in this study.

After this recalibration, the inter-laboratory variability (inter-lab CV) decreased for all the reference materials, with the number of outliers significantly reduced (Fig. 6 and Supplementary Figs. 4–6). For the DB RM, inter-lab CVs were reduced 5-fold for all four ceramide species. For hTAG and YAA RM the CV value decreased 2-fold. However, the final mean values did not show any significant difference after harmonization. Although it delivers final concentration values relative to the shared reference (SRM 1950), this approach improves comparability between measurements generated with different methods or instruments. The differences between the normalised inter-lab CV values for the various SRMs possibly reflect the influence of matrix effects. Similarly, matrix effects of individual plasma samples in clinical studies will affect the reported concentrations, something that may need to be investigated further. While we consider the use of authentic labelled standards essential to yield quantitative results with low inter-laboratory and cross-platform CV (above), we show here that adding this normalisation approach can reduce systematic errors significantly. Even rather severe outlier values (e.g., #34) are realigned with the rest of the participants when using this approach. This last example illustrates well that for better transparency and for future applications, we suggest reporting not only the harmonized concentration values but the ones generated before and after recalibration.

Discussion

Our results demonstrate that, independent of the pre-analytical steps, separation method and type of mass spectrometer used for measurements, our community was able to provide reproducible data from a targeted lipidomic approach, when provided normalization procedures using corresponding labelled standards^{46,47}. This inter-laboratory and cross-platform trial yielded excellent reproducibility, albeit only for a small number of analytes. This good reproducibility was achieved even if we did not recommend any system suitability test




Fig. 5 | Authentic vs non authentic internal standard normalization and its effects on quantification for SRM 1950 RM. Authentic vs non authentic internal standard normalization and its effects on bias and variability. The horizontal bars correspond to the mean and $\pm 1 \times \text{SD}$ of all shown data per group (number of data points indicated for each group). Data originating from the same laboratory are connected by dashed lines. SOP (red) and OTHER (blue) refer to the Standard vs other methods, respectively. Outliers in the authentic internal standard groups have been removed in all groups for each ceramide species (see Fig. 1 and text). Additionally, dataset 11 was excluded for Cer16:0 as it had 15x higher concentrations than the second highest data point for C24:0 d7 normalization.




Fig. 6 | Re-calibration of RM results using SRM 1950 as a shared reference materials. Concentration of the 4 reported ceramides in NIST RM 8231-1 (DB) plasma before and after re-calibration using the NIST SRM 1950 concentration. Each circle corresponds to one measurement from one NIST DB sample shipped to each of the participating laboratories before (None) and after (SRM 1950) re-

calibration with the SRM1950 concentration of the corresponding laboratory (see text). The horizontal bars correspond to the mean $\pm 1 \times$ SD of all shown data per group (number of data points indicated for each group). This plot contains all datasets before and after re-calibration, no outlier removal has been performed.

procedures to optimize the performances of the analytical systems prior to analysis. We highlight the importance of using labelled standards authentic to the endogenous analyte of interest to improve the accuracy of the reported concentrations in a sample and reduce the variability associated with such measurements (Fig. 5, Supplementary Fig. 3). The reasons for the findings illustrated in Fig. 5, where increased variability between participants is associated with the use of class-specific standards instead of authentic ones, were inconclusive. However, one could consider matrix effects (e.g., at different retention times and different in-source ionization efficiency), as well as fragmentation conditions/efficiencies for the different analytes, to exert a relevant effect. Some of these factors could possibly be excluded by using HILIC/SFC separations or FIA, allowing co-elution of the analyte with the surrogate standard, improving on the homogeneity of matrix effects with co-elution, and by the optimization of the ionization, transport, and fragmentation of each single lipid species, although the number of such datasets in our study was too small to draw a definitive conclusion. In this study, most analytes were fragmented with the same or very comparable collision energies despite displaying different chain lengths. In the absence of authentic labelled standards, it has been shown for different lipid species that accurate quantitation requires the use of individual response factors, determined for each molecular species⁴⁸. Structural features (chain length and number of double bonds) and coelution with other analytes can influence ionization and in-source fragmentation, when present, which also depends on the individual setup of the mass spectrometer used.

A second notable aspect included in this work is the comparison of single-point calibration vs. standard curves to generate final concentration values. While the use of calibration curves is an accepted requirement in clinical chemistry, many research laboratories rely on single-point calibration after testing for linearity under the experimental conditions used. Specifically, we compared the reference values generated with the two methodologies and their associated CV. While the variability (CV) between participants was comparable, when using the two methods we did not obtain the same concentration values for Cer16 and Cer18 (Fig. 2). This might be because in our calibration standard mix for Cer16 and Cer18 equimolar solutions of labelled and non-labelled standards did not produce identical areas.

This might point to a deuterium effect during ionization and fragmentation or small differences in the concentrations of standards. This was noticed during the calibration curve measurement and affected the calculated final values. We can also highlight that according to the use of fit-for-purpose calibration curves, we would now design differently the concentration intervals for the standards used to build the calibration curves used here. After measuring the highest and lowest values in the reference materials and in order to increase the accuracy of the results, a dilution series spanning a smaller concentration range, and with a median close to the value we report here for each ceramide, would be a preferable choice.

Analysis of outliers

We found concordant final concentrations (inter-laboratory CV < 30%) between participants. However, to find potential causes of variability and improve future studies, we dedicated some attention to understanding the most divergent values. We decided to classify “outliers” based on Tukey’s $1.5 \times$ IQR fences, corresponding to approximately $3 \times$ SD^{37,49}. This outlier removal method was used to filter the dataset before calculating the average consensus concentrations of the four ceramides in NIST SRM 1950; see also Fig. 1. As we systematically reported results based on both single-point and multi-point calibrations, we noticed that some of the outliers resulting from the use of the single-point calibration were ‘corrected’ and re-aligned to the average value when using multi-point calibration instead (e.g., #04 and #20; Fig. 1, Supplementary Fig. 2). However, as the opposite was observed in specific cases (#17), we conclude that while in principle the use of a calibration curve can help generate more accurate values by developing a response function in the expected range of concentrations of the analytes in unknown samples, sometimes it might also introduce variations due to more tedious protocols. In addition, some measurements were identified as outliers with both calibration methods. When considering the outliers, we did not notice any specific bias towards datasets generated with the recommended SOP or OTHER methods and in terms of the instrument used. We next carefully inspected several of these outliers (Fig. 1). We contacted participants to manually check raw data to exclude possible errors due to peak integration and/or calculations. This in-depth analysis provided

satisfactory explanations for some of the original discrepancies, while we can highlight several useful observations for others. As an example, several participants returned higher values for Cer18 and Cer24:1 when compared to the average of all measurements. These values were generated using a preferred method that included acquisition on a high-resolution instrument, in MS1 only, and identification based on accurate mass of the precursor ion, retention time and co-elution with the labelled standard. It is possible that when measuring the intact mass of ceramides in high-resolution MS (but without sufficient chromatographic separation, e.g., via HILIC or reversed phase with short gradients) without using any correction during quantitation, the resulting peak area might include contributions from isomeric or isobaric compounds present in solution or generated during ionization. With chromatographic conditions unable to separate possible isomers of the target analytes (such as Cer 16:1;O2/20:0 or Cer 18:2;O2/24:0), a partial contribution to the signal of Cer18 and Cer24:1 would have been included with the reported value. When we independently estimated the levels of Cer 16:1;O2/20:0 or Cer 18:2;O2/24:0 in SRM 1950 plasma by LC-MRM, we confirmed the existence of a substantial contribution (10–15% and 30%, respectively) to the MS1 signal of Cer18 and Cer 24:1. After this was taken into account, the values could be aligned with the rest of the participants.

Another source of error was due to copy/paste mistakes (e.g., swapping values between two different ceramide species when generating calibration curves or preparing the final data report). These are quite common errors that lead to the recommendation of using automated procedures, even for data management. At the same time, an outlier characterized by significantly lower values for all ceramides (#34) was likely the result of the erroneous addition of internal standard volumes. In this case, all analytes showed 3-fold lower values compared to the average of participants.

Although each individual outlier value was examined and possible reasons were discussed with the corresponding participants, we could not clarify all the cases reported. Possible factors could include LC-related suppression by coeluting analytes and ionization factors that are MS platform-dependent and that we described earlier in this section, even considering that isotopically labelled analogues are the best solution to counteract matrix effects⁵⁰.

Two laboratories were not able to receive plasma samples of human origin, but only organic lipid extracts thereof. As a result, we had the opportunity to evaluate extract stability for this kind of analysis. Human plasma lipid extracts were prepared in Singapore, following the procedure described in the SOP, and were subsequently shipped to the respective participants. Upon package arrival, one of the recipients noticed that some of the vials containing the lipid extracts were not properly sealed any longer, with significant portions being spilled resulting in smaller volumes of samples available. Nevertheless, it was decided to proceed with the analysis as planned. Interestingly, the results from both participants receiving extracts instead of plasma fully aligned with the mean of the other values. This underscores again the importance of adding isotopically labelled authentic standards in such complex mixtures at the beginning of sample processing to compensate for possible variations during the entire procedure.

Value of this study for the development of reference materials and calibration standards

NIST SRM 1950 (“Metabolites in Frozen Human Plasma”) was prepared from 100 individuals representing the demographic diversity in the United States. A primary utilization purpose was to serve as a reference material of ‘normal’ human blood plasma for validation studies. The original three layers of content characterization provided by NIST are (i) certified values, (ii) reference values and (iii) information values, in decreasing order of metrological uncertainty (<https://www-s.nist.gov/srmors/certificates/1950.pdf>). For example, mass concentrations of

cholesterol and total glycerides (as triolein) are certified values (category of highest accuracy confidence) determined by isotope dilution gas chromatography mass spectrometry after hydrolysis and derivatization. Levels of other lipid-related metabolites (e.g., fatty acids, vitamin D) are combinations of certified and reference values. We show here that generating these values can have a big impact on the normalization of results obtained with different methods and instruments by different laboratories and that harmonization using a shared RM, in addition to the calibration with authentic standards, decreases significantly inter-lab variability. We are aware that this might not be yet a perfect solution to solve the reproducibility issues in the field and that more investigations are needed to clarify other aspects of this process, such as the commutability of the SRM 1950 for specific lipid measurements intended “as the equivalence of the mathematical relationships between the results of different measurement procedures for a reference material and for representative samples from healthy and diseased individuals”⁵¹. However, we think that this approach is valuable in decreasing systematic biases between platforms and our data support this. Our community is also aware that there are limitations when using SRM 1950 for harmonization, for example its cost and possible limited availability in the future. As alternatives, either a cheaper laboratory-specific Long Term Reference sample or a complex mixture of labelled lipids could be considered, as explained elsewhere³⁰. To serve the expanding research communities in metabolomics with reference materials representing different analytical purposes, populations, and diseases, NIST has initiated the development of new lines of RM (e.g., system suitability, human milk, proteomics among others). RM 8231 is a package of three pooled human plasma materials including RM 8231-1 (DB), RM 8231-2 (hTAG), and RM 8231-3 (YAA)²³. Unlike SRM 1950, the above RM 8231s are prepared from a smaller number of individuals ($n=11$, $n=11$, and $n=16$, respectively) and are not documented with certified or reference values to the level of SRM 1950. As mentioned earlier, a notable development over the past decade is the expansion of community efforts aimed at standardization. Collaboration between metrological institutions and interest groups in Quality Assurance and Quality Control is a promising future opportunity for the co-development of RMs, their characterization, validation and eventually certification³², (https://lipidomicsociety.org/interest_groups/reference-materials-and-biological-reference-ranges/). Here we added value to these efforts by providing the most precise publicly available absolute concentration values reported to date for four clinically used ceramides, not only in the commonly used SRM 1950 but also the other RMs as well.

The standards used in this study originated from the same synthetic batch. A single vial containing these four ceramides is commercially available as Deuterated Ceramide LIPIDOMIX® Mass Spec Standard (Avanti Polar Lipids, Cat. #330713). However, the relative concentrations of #330713 differ from those used in this study. It can be expected that our results will encourage the development of precise standard mixtures similar to the one used within this study, as well as future generation of standards, including other stable isotope derivatives of endogenous species.

Relevance for the utility of ceramides in clinical testing

It should be noted that this study constituted a technical phase to address inter-laboratory and cross-platform variability rather than biological variations. However, it forms the basis for the latter to be addressed in future initiatives (e.g., RI in populations or RCV in individuals). Recently, Ramos and colleagues at the Mayo Clinic measured the concentration of these four ceramides in 24 healthy individuals and showed that the variability of ceramide levels at different time points is minimal within individuals⁵². Moreover, when comparing the absolute concentrations of ceramides in these 24 individuals with the results of our study, we notice a good agreement. Establishing

reference values in RMs representative of specific disease conditions was also a propaedeutic exercise for the next phase of our study. These could be from cohorts collected for different studies worldwide, including bio-banked samples. As it is clear from Fig. 3, each specific condition and plasma matrix will require dedicated attention to generate characteristic concentration values that will advance the understanding of the role that ceramides may play in a range of human health and disease conditions.

In summary

- This study represents the largest, most targeted public inter-laboratory and cross-platform ring trial for distinct ceramides in human plasma.
- Standardization of the analytical process helps decreasing variability, but it is not a fundamental requirement to obtain concordant results across multiple laboratories, instruments, and operators.
- We report mean absolute concentration values rather than medians or means of medians. The research and medical community can utilize these reference values as quality control and a quantitative benchmark for ceramides in the reference materials.
- Usage of authentic stable isotope labelled standards for each metabolite of interest reduces variability in inter-laboratory comparisons.
- Recalibration with a shared reference material decreases inter-laboratory variability even further.
- Comparison of pooled plasma samples provides an estimation of biological variation that can be expected between healthy individuals and those with hyperlipidemia as well as an approximation of inter-ethnic differences.
- Despite the highly systematic approach we cannot rule out potential biases of our results from the ‘true’ endogenous ceramide concentrations in human plasma. These remain unresolved and depend on details of preparation procedures of the RM and accuracy of the quality and quantity of the utilized calibration standards.

Methods

Study design

Coordinators. The role of the coordination team within the reference materials and biological reference range interest group of the International Lipidomic Society (<https://lipidomicsociety.org/interest-groups/reference-materials-and-biological-reference-ranges/>) which included Federico Torta, Nils Hoffmann, Robert Ahrends, John Bowden, Kim Ekroos, Markus Wenk) was to design, plan and execute the study in consultation with its partners (Avanti Polar Lipids, National Institute of Standards and Technology- NIST) and participants (other co-authors of the article listed in alphabetical order). Notable activities in the coordination group were establishing a diverse network of participants, negotiating agreements with institutions and companies that supported the project, preparing recommended protocols and forms for return of results in a standardized format, overseeing the distribution of samples, answering questions from participants and keeping them informed about the progress of the study, and, finally, consolidating data and disseminating results, including this report.

Partners. This project was conducted with the essential support of NIST, which made available the plasma reference materials (RMs), and Avanti Polar Lipids, which prepared customized solutions of labelled and non-labelled standards for all study participants. Avanti furthermore helped with the logistics of the sample (both standards and NIST RMs) distribution.

Samples. A set of samples including four different human plasma RMs and, separately, pre-mixed solutions of ceramide standards

(deuterated and non-deuterated) was shipped to all participants. Exceptions were countries with restrictions on import of human plasma. In these cases, the corresponding RM samples were extracted at the Singapore Lipidomics Incubator, National University of Singapore, according to the Standard Operating Protocol (SOP) and distributed to the participants as final lipid extracts in polypropylene tubes.

Each laboratory was responsible for sample preparation, instrument setup, data collection and raw data analysis. No requirements were set in terms of instrument performances before starting the experiments. Raw data (chromatographic peak areas or signal intensities in case of flow injection analysis) were submitted to the coordinators that assigned a random numerical identifier to each lab and redistributed the anonymized data to the data centre (Forschungszentrum Jülich and University of Vienna) for quality check and analysis. Each laboratory was free to choose between the SOP prepared by the organizers and based on published data³⁵ (19 participants) or performing the analysis according to a method of choice (OTHER, 12 participants) or using both the SOP and OTHER methods (3 participants). OTHER methods differed from the SOP in many ways, as they were based on the favourite protocol of each lab that performed the OTHER (preferred) approach. Variations included the use of different solvents for ceramide extraction, different chromatographic conditions (column type and gradient, direct infusion) and different detection methods by mass spectrometry (MRM vs full scan at high resolution, for example). The laboratories were informed of the identity of the sample types, and all agreed to remain blinded to laboratory IDs (other than their own) throughout data acquisition and publication of the results. Identifying information other than the laboratory ID was also removed from the report forms before data processing, integration and visualization were performed.

Standard protocol and reporting forms

An SOP (included as Supplementary Information) describing the procedures for extraction, with six independent extractions for each material, each extract analysed in triplicates, and absolute quantification of Cer 18:1;O2/16:0, Cer 18:1;O2/18:0, Cer 18:1;O2/24:0 and Cer 18:1;O2/24:1 in human plasma using LC-MS/MS, in multiple reaction monitoring (MRM) mode, was sent to all participants, together with the samples to be analysed. Please see the SOP for more details on samples, calibration curve, quality control (QC) and blanks preparation. In addition, two Excel files for reporting of the results (one for the SOP and one for OTHER method) were prepared by the coordinators and sent to all participants (Supplementary Information).

Human plasma samples

SRM 1950 Metabolites in Frozen Human Plasma and candidate RM 8231 Frozen Human Plasma Suite for Metabolomics (hypertriglyceridemic, diabetic, and African American plasma samples) are reference materials produced by NIST. All NIST plasma samples were collected after informed consent under approved IRB protocols reviewed by the NIST Human Subjects Protection Office. Details on the preparation of SRM 1950 have been previously reported^{23,53,54}. Briefly, Bioreclamation, Inc. (Hicksville, NY) collected whole blood using lithium heparin as the anticoagulant from 100 donors (1:1 male to female ratio; 77% White, 12% African American or Black, 4% Asian, 2% American Indian or Alaskan Native, 5% “other”) between 40 and 50 years of age after an overnight fast and a 72-h abstention from medication. Plasma was obtained by centrifuging the collected blood at 8000 × g for 25 min at 4 °C. Plasma from each donor was thawed once and subsequently blended and aliquoted into individual vials to produce the SRM 1950. The diabetic (DB) plasma material (RM 8231-1) was created by Solomon Park Research Laboratories, Inc. from a pool of five female and six male donors (55% White, 36% African American or Black, 9% Asian) between 34 and 68 years of age after an overnight fast, each meeting the

specified ranges for glucose (>126 mg/dL) and triacylglycerols (<150 mg/dL). The hypertriglyceridemic (hTAG) plasma material (RM 8231-2) was also created by Solomon Park Research Laboratories, Inc. (Kirkland, WA) from a pool of 11 male donors (55% White, 36% African American or Black, 9% Hispanic) between 31 and 72 years of age after an overnight fast, each meeting the NIST-specified ranges for glucose (<100 mg/dL) and triacylglycerols (>300 mg/dL). Plasma for both the hypertriglyceridemic and diabetic materials were obtained by centrifuging the respective collected blood at $1718 \times g$ for 10 min, followed by additional centrifugation at $4300 \times g$. Lithium heparin was used as the anticoagulant, and plasma from each donor was thawed once and blended to make the respective donor pools before aliquoting into individual vials. For the Young African American (YAA) plasma (RM 8231-3), Bioreclamation Inc. (Westbury, NY) collected whole blood using dipotassium ethylenediaminetetraacetic acid (K_2 -EDTA) as the anticoagulant from 16 donors (1:1 male to female ratio) between 20 and 25 years of age after an overnight fast. The 16 units of blood were subsequently thawed and pooled by Solomon Park Research Laboratories in the same manner as the hypertriglyceridemic and diabetic plasma materials. NIST plasma aliquots were thawed, pooled and re-aliquoted for this project. Thawing time was minimized and all pooling and aliquoting was performed under inert nitrogen flow using a robotic enclosed system and the samples were returned to the freezer quickly (the entire activity was approximately 1 h). Aliquots were stored at -80°C until shipped on dry ice to each laboratory. A lipid extract was shipped to those participants that were not able to receive human plasma materials. Details are described in the next sections. Since the scope of this trial was not to compare biofluids such as plasma vs serum⁵⁵ or establish the influence of the type of anticoagulant⁵⁶ on the measured ceramide levels, we only report the measurement of the materials described in this section.

Lipid standards and generation of lipid mixtures

Stable isotope labelled internal standards (referred in the text also as ISTD or simply internal standards) were synthesized and provided by Avanti Polar Lipids as a mixture solution in ethyl acetate: 2-propanol (EtOAc:IPA) 2:8 (v/v) at 99% purity. The concentration value of each standard (0.125 $\mu\text{mol/L}$ Cer 18:1;O2[D7]/16:0, 0.050 $\mu\text{mol/L}$, Cer 18:1;O2[D7]/18:0, 1.500 $\mu\text{mol/L}$ Cer 18:1;O2[D7]/24:0, 0.500 $\mu\text{mol/L}$ Cer 18:1;O2[D7]/24:1, Lot #792537-01-010) was chosen based on previously measured levels of the corresponding endogenous analytes³⁵. Non-labelled standards (2 $\mu\text{mol/L}$ Cer 18:1;O2/16:0, 2 $\mu\text{mol/L}$ Cer 18:1;O2/18:0, 20 $\mu\text{mol/L}$ Cer 18:1;O2/24:0, 20 $\mu\text{mol/L}$ Cer 18:1;O2/24:1, Lot #792536-01-010) were also synthesized and provided by Avanti Polar Lipids as a mixture in EtOAc:IPA 2:8 (v/v) at 99% purity and were used to build a calibration curve through serial dilutions of the starting mixture as described in the SOP included as Supplementary Information. Avanti used quantitative proton nuclear magnetic resonance (QHNMR) to determine potency value and concentration of the products. During this process, the solvent from a known volume of each component is removed under nitrogen gas or by centrifugal evaporation. Approximately 10 mg of NIST traceable QHNMR internal standard are added to each along with 1 mL of deuterated solvent. Samples are analysed by a Bruker 400 MHz NMR spectrometer, with cryoprobe, using a validated quantitative proton method. For data interpretation, the integral response of the internal standard is used to calibrate the response of each component so that an accurate concentration is determined. The variance of this method is 2%. Standard mixtures were formulated by first creating stock solutions of each individual component and quantified through QHNMR (variability of the concentrations were determined to be $\pm 2\%$ during method validation), then diluted to the final concentrations using glass pipetting with accuracy $\pm 0.1\%$ of the intended volume. Individual components of unlabelled and deuterated ceramides were then identified via nominal mass measurement using a QQQ MS. In addition, isotopic

purity was determined using a ratio (including isotopic correction) of the fully labelled species to the incompletely labelled species via Q-TOF MS. As part of a Quality Assurance process, we would recommend that the users should always analyse the pure commercial standards in full scan mode to at least estimate the purity of the labelled compounds before using them for analysis. Our strategy to improve the accuracy of quantitation involved the use of a pre-mixed solution containing a fixed amount of each of the four corresponding deuterated (D7) ceramides. This solution was prepared as a single batch by Avanti Polar Lipids after close consultation with the trial coordinators and distributed as aliquots of the same batch to all participants. This strategy was followed to increase the reproducibility of the absolute concentration values measured by the participants, that were not dependent on potential variations between different lots of internal standard solutions. The stock concentration of each component was determined by QHNMR so that the mixture was formulated at the desired concentrations. The subsequently formulated mixture was then analysed via high resolution, accurate mass measurement by Q-TOF MS. As the four ceramides species are present at different concentrations in human plasma, the group of coordinators established expected average concentration values for each of them before the preparation of the pooled batch. These values, ranging from 0.050 to 1.5 $\mu\text{mol/L}$, were derived from a previous publication³⁵. From this and the fact that the range for the ceramide concentrations is small and linear, it can be expected that single-point calibration was acceptable for absolute quantitation. However, as it is widely accepted in analytical chemistry, and recommended by the international guidelines for analyte quantitation, to prepare a series of standards at different concentrations and build a multi-point calibration curve, a second type of pre-mixed solution consisting of the non-deuterated versions of the four ceramides for the preparation of an external calibration curve was prepared by the provider at higher concentration levels (2 and 20 $\mu\text{mol/L}$, respectively) and distributed to the participants. Due to the presence of endogenous lipids in human plasma and unavailability of lipid-free plasma matrix, calibration line standards were prepared in 5% bovine serum albumin (no specific type was required). As previously reported, curves in plasma and albumin were shown to have identical slopes. Both solutions were kept at -20°C , equilibrated at room temperature and sonicated 10 min before use.

Data reporting, processing and analysis

All data reports were initially checked manually for completeness and conformance with the requested reporting format. Deviations were recorded and corrected, where apparent (e.g., an inverse order of concentration steps for calibration lines or deviation from the reporting format structure). Remarks by participants concerning potential issues during sample preparation or measurement steps were recorded and associated to the specific dataset that was manually examined for a potential bias. Two sets of calibration line model parameters were calculated for each of the four ceramides per dataset, using a $1/x^2$ weighted linear model between the expected concentration and the ratio of unlabelled and labelled ceramide. This model was chosen because of the large range of concentrations measured and because the absolute variation is usually larger for higher concentrations; we therefore tried to limit the error at the bottom of the curve by weighting the data inversely with the concentration, as reported previously. LoD and LoQ concentrations were calculated as averages of the standard error of the intercept of the calibration lines of the STD 6 samples (lowest concentration of the calibration line samples), divided by the slope of the respective calibration line and multiplied by 3.3 (LoD) and 10 (LoQ), due to the lack of consistent Matrix Blanks^{57,58}. Both values were then normalized by the slope of the corresponding calibration curve. Final concentrations for each ceramide were calculated using the averaged output of the two corresponding calibration line models. As a common procedure in lipidomics, for each dataset

and each sample, single-point calibrated concentrations were calculated from the ratio of the corresponding unlabelled and labelled ceramide, multiplied with the internal standard concentration. To compare different normalizations, adjusted concentrations were calculated using calibration curves built with either the authentic or non-authentic labelled internal standards in combination with the authentic non-labelled standard, i.e. Cer 16:0 and Cer 24:0, respectively.

Outlier removal. Calculation of consensus concentrations, inter-lab CVs and data in Figs. 1, 2, 3, 5 and 6 were based on outlier-filtered datasets. The outlier filtering was applied using Tukey's $1.5 \times \text{IQR}$ (inter quantile range) method, which corresponds to approximately a mean $\pm 3 \times \text{SD}$ ^{37,49}. For each lipid species, matrix and quantification approach (single and multi-point calibration), datasets from laboratories with average concentrations below Q1 (1st quantile) $- 1.5 \times \text{IQR}$, or above Q3 $+ 1.5 \times \text{IQR}$ were excluded.

Calculations and visualizations. All calculations were performed in R (version 4.4.1) using R packages targets (1.2.2), tidyverse (version 2.0.0), ggbeeswarm (0.7.2) and ggh4x (0.2.8)^{59–61}.

All raw and processed datasets and the R pipeline used to process, calculate, and plot the data are available from the GitHub repository (<https://github.com/lifs-tools/ils-ceramide-ring-trial>). A detailed list of all R packages and their versions is available in the 'renv.lock' file within the same repository. The GitHub repository version used to prepare the data and figures for this accepted manuscript was archived to Zenodo (<https://zenodo.org/doi/10.5281/zenodo.10081970>).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All raw and processed datasets and the R pipeline used to process, calculate, and plot the data are available from the GitHub repository (<https://github.com/lifs-tools/ils-ceramide-ring-trial>). The GitHub repository version used for this accepted manuscript was archived to Zenodo under the <https://doi.org/10.5281/zenodo.10081970>. All mass spectrometry raw data generated by the participants were deposited to Zenodo under the <https://doi.org/10.5281/zenodo.12632989>. Source data are provided with this paper.

References

- Züllig, T., Trötz Müller, M. & Köfeler, H. C. Lipidomics from sample preparation to data analysis: a primer. *Anal. Bioanal. Chem.* **412**, 2191–2209 (2020).
- Köfeler, H. C. et al. Quality control requirements for the correct annotation of lipidomics data. *Nat. Commun.* **12**, 1–4 (2021).
- Köfeler, H. C. et al. Recommendations for good practice in MS-based lipidomics. *J. Lipid Res.* **62**, 100138 (2021).
- Liebisch, G. et al. Lipidomics needs more standardization. *Nat. Metab.* **1**, 745–747 (2019).
- Meikle, T. G., Huynh, K., Giles, C. & Meikle, P. J. Clinical lipidomics: realizing the potential of lipid profiling. *J. Lipid Res.* **62**, 100127 (2021).
- Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline (Clinical and Laboratory Standards Institute, Wayne, Pa, 2010).
- Harris, E. K. & Yasaka, T. On the calculation of a 'reference change' for comparing two consecutive measurements. *Clin. Chem.* **29**, 25–30 (1983).
- Burla, B. et al. MS-based lipidomics of human blood plasma: A community-initiated position paper to develop accepted guidelines. *J. Lipid Res.* <https://doi.org/10.1194/jlr.S087163> (2018).
- Bikman, B. T. A role for sphingolipids in the pathophysiology of obesity-induced inflammation. *Cell. Mol. Life Sci.* **69**, 2135–2146 (2012).
- Boon, J. et al. Ceramides Contained in LDL Are Elevated in Type 2 Diabetes and Promote Inflammation and Skeletal Muscle Insulin Resistance. *Diabetes* **62**, 401–410 (2013).
- Haus, J. M. et al. Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance. *Diabetes* **58**, 337–343 (2009).
- Havulinna, A. S. et al. Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort. *Arteriosclerosis Thrombosis Vasc. Biol.* **36**, 2424–2430 (2016).
- Nicholson, R. J., Holland, W. L. & Summers, S. A. Ceramides and Acute Kidney Injury. *Seminars Nephrol.* **42**, 151281 (2022).
- Schumacher, F. et al. Ceramide levels in blood plasma correlate with major depressive disorder severity and its neutralization abrogates depressive behavior in mice. *J. Biological Chem.* **298**, 102185 (2022).
- Laaksonen, R. et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. *Eur. Heart J.* **37**, 1967–1976 (2016).
- Poss, A. M. et al. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. *J. Clin. Invest.* **130**, 1363–1376 (2020).
- Alexandropoulou, I. et al. Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment. *Nutrients* **15**, 229 (2023).
- Carrard, J. et al. How Ceramides Orchestrate Cardiometabolic Health—An Ode to Physically Active Living. *Metabolites* **11**, 675 (2021).
- Skácel, J., Slusher, B. S. & Tsukamoto, T. Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network. *J. Med. Chem.* **64**, 279–297 (2021).
- Park, T.-S., Rosebury, W., Kindt, E. K., Kowala, M. C. & Panek, R. L. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. *Pharmacol. Res.* **58**, 45–51 (2008).
- Blaho, V. A. Druggable sphingolipid pathways: Experimental models and clinical opportunities. In *Druggable lipid signaling pathways* (ed. Kihara, Y.) 101–135 (Springer International Publishing, Cham, 2020). https://doi.org/10.1007/978-3-030-50621-6_6.
- McGurk, K. A. et al. Heritability and family-based GWAS analyses of the N-acyl ethanolamine and ceramide plasma lipidome. *Hum. Mol. Genet.* **30**, 500–513 (2021).
- Aristizabal-Henao, J. J., Jones, C. M., Lippa, K. A. & Bowden, J. A. Nontargeted lipidomics of novel human plasma reference materials: hypertriglyceridemic, diabetic, and African-American. *Anal. Bioanal. Chem.* **412**, 7373–7380 (2020).
- Bowden, J. A. et al. Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950—Metabolites in Frozen Human Plasma[S]. *J. Lipid Res.* **58**, 2275–2288 (2017).
- Lange, M. & Fedorova, M. Evaluation of lipid quantification accuracy using HILIC and RPLC MS on the example of NIST® SRM® 1950 metabolites in human plasma. *Anal. Bioanal. Chem.* **412**, 3573–3584 (2020).
- Misra, B. B. & Olivier, M. High Resolution GC-Orbitrap-MS Metabolomics Using Both Electron Ionization and Chemical Ionization for Analysis of Human Plasma. *J. Proteome Res.* **19**, 2717–2731 (2020).
- Quehenberger, O. et al. Lipidomics reveals a remarkable diversity of lipids in human plasma 1 [S]. *J. Lipid Res.* **51**, 3299–3305 (2010).
- Siskos, A. P. et al. Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. *Anal. Chem.* **89**, 656–665 (2017).

29. Thompson, J. W. et al. International Ring Trial of a High Resolution Targeted Metabolomics and Lipidomics Platform for Serum and Plasma Analysis. *Anal. Chem.* **91**, 14407–14416 (2019).
30. Triebel, A. et al. Shared reference materials harmonize lipidomics across MS-based detection platforms and laboratories. *J. Lipid Res.* **61**, 105–115 (2020).
31. Chocholoušková, M. et al. Intra-laboratory comparison of four analytical platforms for lipidomic quantitation using hydrophilic interaction liquid chromatography or supercritical fluid chromatography coupled to quadrupole - time-of-flight mass spectrometry. *Talanta* **231**, 122367 (2021).
32. Lippa, K. A. et al. Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC). *Metabolomics* **18**, 24 (2022).
33. Ghorasaini, M. et al. Cross-Laboratory Standardization of Preclinical Lipidomics Using Differential Mobility Spectrometry and Multiple Reaction Monitoring. *Anal. Chem.* **93**, 16369–16378 (2021).
34. Hammad, S. M. et al. Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity. *PLOS ONE* **14**, e0224496 (2019).
35. Kauhanen, D. et al. Development and validation of a high-throughput LC–MS/MS assay for routine measurement of molecular ceramides. *Anal. Bioanal. Chem.* **408**, 3475–3483 (2016).
36. Liebisch, G. et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. *J. Lipid Res.* **61**, 1539–1555 (2020).
37. Tukey, J. W. *Exploratory Data Analysis* (Addison-Wesley Publishing Company, 1977).
38. Cadby, G. et al. Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study [S]. *J. Lipid Res.* **61**, 537–545 (2020).
39. Tabassum, R. et al. Genetic architecture of human plasma lipidome and its link to cardiovascular disease. *Nat. Commun.* **10**, 4329 (2019).
40. Beyene, H. B. et al. High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. *PLoS Biol.* **18**, e3000870 (2020).
41. Vesper, H. W., Myers, G. L. & Miller, W. G. Current practices and challenges in the standardization and harmonization of clinical laboratory tests. *Am. J. Clin. Nutr.* **104**, 907S–912S (2016).
42. Myers, G. L. & Miller, W. G. The International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR) - A Pathway for Harmonization. *EJIFCC* **27**, 30–36 (2016).
43. Diepeveen, L. E. et al. Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material. *Clin. Chem. Lab. Med.* **57**, 864–872 (2019).
44. Pickens, C. A. et al. Harmonizing Newborn Screening Laboratory Proficiency Test Results Using the CDC NSQAP Reference Materials. *Int. J. Neonatal Screen.* **6**, 75 (2020).
45. Harmonization.net. *The International Consortium for Harmonization of Clinical Laboratory Results*, <https://www.harmonization.net/>.
46. Schoeny, H. et al. A combined flow injection/reversed-phase chromatography–high-resolution mass spectrometry workflow for accurate absolute lipid quantification with ¹³C internal standards. *Analyst* **146**, 2591–2599 (2021).
47. Lehmann, W. D. A timeline of stable isotopes and mass spectrometry in the life sciences. *Mass Spectrom. Rev.* **36**, 58–85 (2017).
48. Höring, M., Ejlsing, C. S., Hermansson, M. & Liebisch, G. Quantification of Cholesterol and Cholesteryl Ester by Direct Flow Injection High-Resolution Fourier Transform Mass Spectrometry Utilizing Species-Specific Response Factors. *Anal. Chem.* **91**, 3459–3466 (2019).
49. Hickman, P. E. et al. Choice of Statistical Tools for Outlier Removal Causes Substantial Changes in Analyte Reference Intervals in Healthy Populations. *Clin. Chem.* **66**, 1558–1561 (2020).
50. Berg, T. & Strand, D. H. ¹³C labelled internal standards—A solution to minimize ion suppression effects in liquid chromatography–tandem mass spectrometry analyses of drugs in biological samples? *J. Chromatogr. A* **1218**, 9366–9374 (2011).
51. Vesper, H. W., Miller, W. G. & Myers, G. L. Reference materials and commutability. *Clin. Biochem. Rev.* **28**, 139–147 (2007).
52. Ramos, P. et al. The Biological Variability of Plasma Ceramides in Healthy Subjects. *J. Appl. Lab. Med.* **7**, 863–870 (2022).
53. Phinney, K. W. et al. Development of a Standard Reference Material for Metabolomics Research. *Anal. Chem.* **85**, 11732–11738 (2013).
54. Simón-Manso, Y. et al. Metabolite Profiling of a NIST Standard Reference Material for Human Plasma (SRM 1950): GC-MS, LC-MS, NMR, and Clinical Laboratory Analyses, Libraries, and Web-Based Resources. *Anal. Chem.* **85**, 11725–11731 (2013).
55. Wolrab, D., Chocholoušková, M., Jirásko, R., Peterka, O. & Holčápek, M. Validation of lipidomic analysis of human plasma and serum by supercritical fluid chromatography–mass spectrometry and hydrophilic interaction liquid chromatography–mass spectrometry. *Anal. Bioanal. Chem.* **412**, 2375–2388 (2020).
56. Wolrab, D. et al. Determination of one year stability of lipid plasma profile and comparison of blood collection tubes using UHPSFC/MS and HILIC-UHPLC/MS. *Analytica Chim. Acta* **1137**, 74–84 (2020).
57. Currie, L. A. Nomenclature in evaluation of analytical methods including detection and quantification capabilities (IUPAC Recommendations 1995). *Pure Appl. Chem.* **67**, 1699–1723 (1995).
58. Magnusson, B. & Örnemark, U. *The Fitness for Purpose of Analytical Methods - A Laboratory Guide to Method Validation and Related Topics* (Eurachem, 2014).
59. Clarke, E., Sherrill-Mix, S. & Dawson, C. *Ggbeeswarm: Categorical Scatter (Violin Point) Plots*. <https://CRAN.R-project.org/package=ggbeeswarm> (2023).
60. van den Brand, T. *Ggh4x: Hacks for 'Ggplot2'*. <https://CRAN.R-project.org/package=ggh4x> (2023).
61. Wickham, H. et al. Welcome to the Tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).

Acknowledgements

1,2 Work in the MRW laboratory is supported by grants from the National University of Singapore via the Life Sciences Institute (LSI) and A*STAR IAF-ICP I1901E0040. 4 N.H. acknowledges support by de.NBI and the de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI) and ELIXIR-DE (Forschungszentrum Jülich and W-de.NBI-001, W-de.NBI-004, W-de.NBI-008, W-de.NBI-010, W-de.NBI-013, W-de.NBI-014, W-de.NBI-016, W-de.NBI-022). 5 Bundesministerium für Bildung, Wissenschaft und Forschung“ BMBF within the project DigiOmics4Austria. 6 Work in the SALB laboratory is supported by grants from the Canadian Institutes of Health Research and the Canadian Consortium on Neurodegeneration and Aging CAN-CIHR 163902 and PJT 183604. 7,8,55,56 H.T. was supported by JSPS KAKENHI (21K18216 to Hiroshi T.), the National Cancer Centre Research and Development Fund (2020-A-9, H.T.), and JST ERATO Grant (JPMJER2101 to H.T.). 9 This research is partly supported by AMED-BINDS (JP23ama121055), JST A-STEP (JPMJTR204J), JST-NBDC (JPMJND2305), and the MEXT Cooperative Research Project Program, Medical Research Center Initiative for High Depth Omics, and CURE:JPMXP1322015486 for the Medical Institute of Bioregulation, Kyushu University. 10 Work in MetaToul (Toulouse metabolomics & fluxomics facilities, www.mth-metatoul.com) part of the French National Infrastructure for Metabolomics and Fluxomics is supported by MetaboHUB-ANR-11-INBS-0010 and Inserm (French National Institut for Research in Health). 13 Work at the University of Manchester supported in part by grants from the British Heart Foundation (PG/2019/34923) and BBSRC (BB/W006022/1). 16 Work at University

of Pardubice was supported by grant No. 21-20238S (Czech Science Foundation) and ERC Adv grant No. 101095860 (European Research Council). 19 Work in the MTS department is supported by the Metabo-HUB infrastructure (ANR-11-INBS-0010 grant). 21 BBSRC for funding to the Babraham Institute and to Michael Wakelam's memory for his life of contribution to the lipidomics world. 23 Mass spectrometric analysis was performed at the Turku Metabolomics Centre with the support of Biocenter Finland. 24,25,26 This publication is based upon work from COST Action EpiLipidNET, Pan-European Network in Lipidomics and EpiLipidomics (CA19105; <https://www.epilipid.net>), supported by COST (European Cooperation in Science and Technology). 30 M.G. is an early-stage researcher supported by the H2020 ITN consortium ArthritisHeal (#812890). M.G. was partially supported by the NWO XOmics project #184.034.019. 31 Nanyang Assistant Professorship, Lee Kong Chian School of Medicine, Nanyang Technological University. 36 Supported by grants from the National Natural Science Foundation of China (21934006 and 22074144). 48 Ser Cymru Project Sepsis grant funded by Welsh Government/EU-ERDF (VJT, VBO). 51,52 Supported by the Tohoku Medical Megabank Project from MEXT, the Japan Agency for Medical Research and Development (AMED; under grant numbers JP20km0105001 and JP21tm0124005) and KAKENHI Grant Number JP23H02625 [D.S.]. 54 The Christian Doppler Laboratory for Innovative Gut Health Concepts of Livestock has been funded by the Austrian Federal Ministry for Digital and Economic Affairs, the Austrian National Foundation for Research, Technology and Development as well as BIOMIN Holding GmbH, which is part of DSM. The authors also thank Marco Reiter for technical support. The participants would like to acknowledge Clay Davis from the National Institute of Standards and Technology. B.B. would like to acknowledge Christian Luechtenborg for his contribution to this project.

Author contributions

All authors contributed to the work presented in this paper for the experimental part, data analysis and in assembling the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-024-52087-x>.

Correspondence and requests for materials should be addressed to Kim Ekroos, Robert Ahrends or Markus R. Wenk.

Peer review information *Nature Communications* thanks Karolina Sulek and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2024

Federico Torta^{1,2,3,62}, Nils Hoffmann^{4,5,62}, Bo Burla^{1,62}, Irina Alecu⁶, Makoto Arita^{7,8}, Takeshi Bamba⁹, Steffany A. L. Bennett⁶, Justine Bertrand-Michel¹⁰, Britta Brügger¹¹, Mónica P. Cala¹², Dolores Camacho-Muñoz¹³, Antonio Checa¹⁴, Michael Chen¹⁵, Michaela Chocholoušková¹⁶, Michelle Cinel^{17,18}, Emeline Chu-Van¹⁹, Benoit Colsch¹⁹, Cristina Coman⁵, Lisa Connell²⁰, Bebiana C. Sousa²¹, Alex M. Dickens^{22,23}, Maria Fedorova^{24,25,26}, Finnur Freyr Eiriksson^{27,28}, Hector Gallart-Ayala²⁹, Mohan Ghorasaini³⁰, Martin Giera³⁰, Xue Li Guan³¹, Mark Haid³², Thomas Hankemeier³³, Amy Harms³³, Marcus Höring³⁴, Michal Holčapek¹⁶, Thorsten Hornemann³⁵, Chunxiu Hu³⁶, Andreas J. Hülsmeier³⁵, Kevin Huynh^{17,18}, Christina M. Jones³⁷, Julijana Ivanisevic²⁹, Yoshihiro Izumi⁹, Harald C. Köfeler³⁸, Sin Man Lam^{39,40}, Mike Lange^{24,25}, Jong Cheol Lee⁴¹, Gerhard Liebisch³⁴, Katrice Lippa³⁷, Andrea F. Lopez-Clavijo²¹, Malena Manzi^{42,43,44}, Manuela R. Martinefski^{42,45}, Raviswamy G. H. Math⁴⁶, Satyajit Mayor⁴⁶, Peter J. Meikle^{17,18}, María Eugenia Monge⁴², Myeong Hee Moon⁴¹, Sneha Muralidharan^{1,46}, Anna Nicolaou^{13,47}, Thao Nguyen-Tran⁶, Valerie B. O'Donnell⁴⁸, Matej Orešič^{22,49}, Arvind Ramanathan⁵⁰, Fabien Riols³², Daisuke Saigusa^{51,52}, Tracey B. Schock⁵³, Heidi Schwartz-Zimmermann⁵⁴, Guanghou Shui⁴⁰, Madhulika Singh³³, Masatomo Takahashi⁹, Margrét Thorsteinsdóttir^{27,28}, Noriyuki Tomiyasu⁹, Anthony Tournadre¹⁰, Hiroshi Tsugawa^{7,8,55,56}, Victoria J. Tyrrell⁴⁸, Grace van der Gugten⁵⁷, Michael O. Wakelam²¹, Craig E. Wheelock^{14,58}, Denise Wolrab¹⁶, Guowang Xu³⁶, Tianrun Xu³⁶, John A. Bowden⁵⁹, Kim Ekroos⁶⁰ ✉, Robert Ahrends⁵ ✉ & Markus R. Wenk^{1,2,61} ✉


¹Singapore Lipidomics Incubator, Life Sciences Institute, National University of Singapore, Singapore 117456, Singapore. ²Precision Medicine Translational Research Programme and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore.

³Signature Research Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore (NUS) Medical School, Singapore 169857, Singapore. ⁴Institute for Bio- and Geosciences (IBG-5), Forschungszentrum Jülich GmbH, 52428 Jülich, Germany. ⁵Department of Analytical Chemistry,


University of Vienna, Vienna, Austria. ⁶Neural Regeneration Laboratory, Ottawa Institute of Systems Biology, Ottawa Brain and Mind Research Institute, Department of Biochemistry, Microbiology, and Immunology, and Department of Chemistry, Centre for Catalysis Research and Innovation, University of Ottawa, Ottawa K1H 8M5, Canada. ⁷RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ⁸Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan. ⁹Division of Metabolomics Center, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. ¹⁰MetaboHUBMetaToul Facility, I2MC U1297 Inserm, Toulouse, France. ¹¹Heidelberg University Biochemistry Center (BZH), Im Neuenheimer Feld 328, 69120 Heidelberg, Germany. ¹²Metabolomics Core Facility-MetCore, Universidad de los Andes, Bogotá 111711, Colombia. ¹³Laboratory for Lipidomics and Lipid Biology, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9NT, United Kingdom. ¹⁴Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ¹⁵Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. ¹⁶Department of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic. ¹⁷Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia. ¹⁸Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Bundoora, VIC 3086, Australia. ¹⁹Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), MetaboHUB, F-91191 Gif sur Yvette, France. ²⁰Avanti Polar Lipids, Alabaster, AL, USA. ²¹Babraham Institute, Babraham Research Campus, Cambridge, MA CB22 3AT, USA. ²²Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland. ²³Department of Chemistry, University of Turku, Turku, Finland. ²⁴Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, University of Leipzig, 04013 Leipzig, Germany. ²⁵Center for Biotechnology and Biomedicine, University of Leipzig, 04013 Leipzig, Germany. ²⁶Center of Membrane Biochemistry and Lipid Research, Faculty of Medicine Carl Gustav Carus of TU Dresden, 01307 Dresden, Germany. ²⁷Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland. ²⁸ArcticMass, Reykjavik, Iceland. ²⁹Metabolomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. ³⁰Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands. ³¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921, Singapore. ³²Metabolomics and Proteomics Core, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg 85764, Germany. ³³Metabolomics and Analytics Centre, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. ³⁴University Hospital of Regensburg, Institute of Clinical Chemistry and Laboratory Medicine, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. ³⁵Institute of Clinical Chemistry, University Zurich, 8952 Schlieren, Switzerland. ³⁶State Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. ³⁷Chemical Science Division, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA. ³⁸Core Facility Mass Spectrometry, Medical University of Graz, 8010 Graz, Austria. ³⁹LipidALL Technologies, Changzhou 213000 Jiangsu, China. ⁴⁰State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China. ⁴¹Department of Chemistry, Yonsei University, Seoul 03722, South Korea. ⁴²Centro de Investigaciones en Bionanociencias (CIBION), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2390, C1425FQD Ciudad de Buenos Aires, Argentina. ⁴³Departamento de Fisiología, Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Intendente Güiraldes, 2160 C1428EGA, Buenos Aires, Argentina. ⁴⁴Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Departamento de Desarrollo Analítico y Control de Procesos, Instituto Nacional de Tecnología Industrial, Av. General Paz 5445, B1650WAB Buenos Aires, Argentina. ⁴⁵Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Ciencias Químicas, Buenos Aires, Junin 954, Junin C1113AAD CABA, Argentina. ⁴⁶National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, Karnataka 560065, India. ⁴⁷Lydia Becker Institute of Immunology and Inflammation; Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9NT, United Kingdom. ⁴⁸Systems Immunity Research Institute, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. ⁴⁹School of Medical Sciences, Faculty of Medicine and Health, Örebro University, 702 81 Örebro, Sweden. ⁵⁰Institute for Stem Cell Science and Regenerative Medicine, 560065 Bangalore, India. ⁵¹Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. ⁵²Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8573, Japan. ⁵³Chemical Science Division, National Institute of Standards and Technology, Charleston, SC 29412, USA. ⁵⁴Christian Doppler Laboratory for Innovative Gut Health Concepts of Livestock, Institute of Bioanalytics and Agro-Metabolomics, Department of Agrobiotechnology (IFATulln), University of Natural Resources and Life Sciences, Vienna (BOKU), Konrad-Lorenz-Str. 20, 3430 Tulln, Austria. ⁵⁵RIKEN Center for Sustainable Resource Science, Yokohama, Japan. ⁵⁶Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Tokyo, Japan. ⁵⁷St. Paul's Hospital, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada. ⁵⁸Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden. ⁵⁹Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA. ⁶⁰Lipidomics Consulting Ltd., Espoo, Finland. ⁶¹College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar. ⁶²These authors contributed equally: Federico Torta, Nils Hoffmann, Bo Burla.

✉ e-mail: kim@lipidomicsconsulting.com; robert.ahrends@univie.ac.at; mwenk@hbku.edu.qa

SUPPLEMENTARY FIGURES




Supplementary Figure 1. Log-log plot of mean calibration lines over all participating labs and protocols. Each concentration step of the calibration line samples is depicted as a blue dot, steps are connected by a blue solid line. The blue ribbons highlight the respective mean $\pm 1\text{SD}$. Median values are indicated by black dots and connected by a grey dashed line. The green line corresponds to the theoretical equimolar response of spiked-in non-labelled and labelled standards. The red line and ribbon correspond to the actual mean area ratios in the measured NIST SRM 1950 RM samples and the mean $\pm 1\text{SD}$, respectively, illustrating the suitability of the calibration lines to capture the expected concentrations of the four ceramides. Source data are provided as Source Data file.




Supplementary Figure 2. Consensus concentrations of ceramides in NIST SRM 1950 across all study participants. Concentration of the 4 reported ceramides in NIST SRM 1950 based on direct quantification using the internal standard (single-point calibration). Each circle corresponds to the mean of 1 to 6 replicate measurements from a vial of NIST SRM 1950 shipped to each of the participating laboratories. The error bars depict $\pm 1 \times \text{SD}$, which in some cases is smaller than the diameter of the plotted circle or absent if only 1 measurement was made. Horizontal bars represent the mean values of the mean measured concentration per NIST vial. The outer green dotted lines indicate Tukey's $Q1 - 1.5 \times \text{interquartile range (IQR)}$ and $Q3 + 1.5 \times \text{IQR}$ used for as cut-off values for outlier removal. The mean $\pm 2 \times \text{SD}$ (solid grey and dashed grey lines) is based on the data after outlier removal. SOP (red) and OTHER (blue) refer to the Standard vs OTHER methods, respectively. Source data are provided as Source Data file.


A



B




Supplementary Figure 3 – Comparison of single-point and multi-point calibrations of the full (A) and outlier-filtered (B) dataset. Molar concentrations derived from single-point vs. multi-point calibration based quantifications. The diagonal line indicates equal results between single-point (horizontal axis) and multi-point (vertical axis) calibration-based quantification. Outlier measurements were removed for each ceramide species in each reference plasma (see Fig. 1 and text). Each circle corresponds to the mean value reported by one laboratory ($n=6$). NIST SRM 1950 (SRM, blue); hypertriglyceridemic (hTAG, red), diabetic (DB, purple), and Young African American (YAA, green), which are part of NIST RM 8231. Source data are provided as Source Data file.




Supplementary Figure 4 – Concentration values of ceramides in NIST SRM 1950 and the suite of human plasma RM contained in RM 8231 of the full (A) and outlier-filtered (B) dataset.


Concentrations of the 4 ceramides in different NIST reference plasma samples. Each circle corresponds to the values reported by one laboratory. P values are based on paired t-tests of complete datasets. The horizontal bars correspond to the mean $\pm 1 \times \text{SD}$ of all points per group. Outlier measurements were removed in (B) for ceramide species in each reference plasma (see Fig.1 and text). SOP (red) and OTHER (blue) refer to the Standard vs Other methods, respectively. Source data are provided as Source Data file.




Supplementary Figure 5 – Comparison of concentration values obtained in this and previous studies covering ceramides by MS-platforms in NIST SRM 1950 with the full (A) and outlier-filtered (B) ILS Ceramides dataset. Comparison of inter-laboratory and/or cross-platform trials reporting ceramide concentrations in NIST SRM 1950. Each open circle corresponds to the reported value from one laboratory in each of the respective studies referenced by first author and year of publication. (sp) refers to a single, standardized protocol and platform employed by all laboratories while (mp) denotes studies in which multiple protocols and platforms were used. The red boxes and numbers indicate median $\pm$ MAD (mean absolute deviation) and the number of participating laboratories, respectively. Depending on the precise nature of the study and/or reporting laboratory, concentrations were either reported with sphingoid-base and fatty acyl chain details (e.g. Cer 18:1;O2/16:0, left panel) or as sum compositions (i.e. Cer 34:1;O2, left panel). In the latter case, isobaric ceramide species other than the 4 ceramides targeted in this study may therefore have contributed to the reported concentrations. Details of the individual studies are presented in Table S3. No outlier removal has been applied for any of the studies. Source data are provided as Source Data file.




Supplementary Figure 6 – Authentic vs non-authentic internal standard normalization and its effects on quantification bias and variability. Concentration of ceramides in SRM 1950 RM for the full (A) and outlier-filtered (B) dataset are based on multi-point calibration. The horizontal bars correspond to the mean and $\pm 1 \times \text{SD}$ of all points per group. Data originating from the same laboratory are connected by dashed lines. SOP (red) and OTHER (blue) refer to the Standard vs other methods, respectively. Outliers in the authentic internal standard groups have been removed (see Fig. 1 and text). In panel B, outliers (found in the authentic internal standard datasets) have been removed in all groups for each ceramide species (see Fig. 1 and text). Dataset 11 was excluded for Cer16:0 in panels A and B, as it showed 15x higher concentration than the second highest data point for C24:0 D7 normalization. The number of data points is indicated for each dataset. Source data are provided as Source Data file.




Supplementary Figure 7 – Authentic vs non-authentic internal standard normalization and its effect on quantitation bias and variability for SRM 1950 RM when using single-point (A) and multi-point (B) calibrated concentrations. The horizontal bars correspond to the mean and $\pm 1 \times \text{SD}$ of all points per group. Data originating from the same laboratory are connected by dashed lines. SOP (red) and OTHER (blue) refer to the Standard vs other methods, respectively. The full dataset is shown here, except of dataset 11 in Cer16:0, excluded from panels A and B as it showed 15x higher concentrations than the second highest data point for C24:0 D7 normalization. The number of data points is indicated for each dataset. Source data are provided as Source Data file.



Supplementary Figure 8. Re-calibration of hTAG using SRM 1950 after multi-point calibration. All datasets are shown, while the indicated %CVs were calculated after exclusion of outliers (see Fig. 1 and text). Source data are provided as Source Data file.



Supplementary Figure 9. Re-calibration of DB using SRM 1950 after multi-point calibration. All datasets are shown here, while the indicated %CVs were calculated after exclusion of outliers (see Fig. 1 and text). Source data are provided as Source Data file.



Supplementary Figure 10. Re-calibration of YAA using SRM 1950 after multi-point calibration. All datasets are shown here, while the indicated %CVs were calculated after exclusion of outliers (see Fig. 1 and text).

SUPPLEMENTARY TABLES

Supplementary Table 1. Concentrations and inter-lab %CVs in all reference materials. ALL and Filt correspond to values calculated from the full or the outlier-filtered dataset, respectively. All concentrations were calculated using multi-point calibration. *n* corresponds to the number of datasets. Source data provided as a Source Data file.

Matrix	Ceramide	$\mu\text{mol/L}$ (ALL)					$\mu\text{mol/L}$ (Filt)				
		<i>n</i>	mean	SD	median	%CV	<i>n</i>	mean	SD	median	%CV
SRM	Cer 18:1;O2/16:0	39	0.2500	0.0612	0.2481	24.5	35	0.2438	0.0336	0.2468	13.8
SRM	Cer 18:1;O2/18:0	39	0.0879	0.0269	0.0857	30.6	31	0.0835	0.0097	0.0844	11.6
SRM	Cer 18:1;O2/24:0	39	2.4888	0.6266	2.4439	25.2	35	2.4116	0.2441	2.4368	10.1
SRM	Cer 18:1;O2/24:1	39	0.9039	0.2422	0.8739	26.8	31	0.8554	0.0724	0.8563	8.5
hTAG	Cer 18:1;O2/16:0	39	0.2914	0.0667	0.2902	22.9	35	0.2888	0.0369	0.2902	12.8
hTAG	Cer 18:1;O2/18:0	39	0.1004	0.0274	0.0994	27.3	31	0.0995	0.0110	0.0994	11.0
hTAG	Cer 18:1;O2/24:0	39	3.8190	0.8533	3.8073	22.3	36	3.7641	0.4587	3.7790	12.2
hTAG	Cer 18:1;O2/24:1	39	1.3186	0.3307	1.2701	25.1	33	1.2784	0.1534	1.2606	12.0
DB	Cer 18:1;O2/16:0	39	0.2242	0.0594	0.2219	26.5	35	0.2161	0.0309	0.2155	14.3
DB	Cer 18:1;O2/18:0	39	0.0993	0.0286	0.0979	28.8	32	0.0966	0.0114	0.0975	11.8
DB	Cer 18:1;O2/24:0	39	2.4525	0.6096	2.4428	24.9	36	2.4013	0.2847	2.4289	11.9
DB	Cer 18:1;O2/24:1	39	0.8919	0.2358	0.8757	26.4	33	0.8663	0.0996	0.8663	11.5
YAA	Cer 18:1;O2/16:0	39	0.1539	0.0451	0.1541	29.3	34	0.1450	0.0227	0.1504	15.6
YAA	Cer 18:1;O2/18:0	39	0.0514	0.0183	0.0494	35.6	34	0.0494	0.0092	0.0494	18.6
YAA	Cer 18:1;O2/24:0	39	1.7503	0.5800	1.6475	33.1	35	1.6485	0.2217	1.6364	13.4
YAA	Cer 18:1;O2/24:1	39	0.5842	0.2006	0.5520	34.3	33	0.5518	0.0775	0.5432	14.0

Supplementary Table 2. Concentrations and inter-lab %CV of ceramide species from the two protocol types. The mean concentrations given in $\mu\text{mol/L}$ are based on multi-point calibration after exclusion of outliers. The *P* values are from the comparison of individual values reported by SOP vs OTHER protocols (Welch's two-sided *t*-test). *n* corresponds to the number of datasets after outlier removal. Source data provided as a Source Data file

Matrix	Ceramide	<i>n</i> (SOP)	<i>n</i> (OTHER)	$\mu\text{mol/L}$ (SOP)	$\mu\text{mol/L}$ (OTHER)	<i>P</i> value	%CV (SOP)	%CV (OTHER)
SRM	Cer 18:1;O2/16:0	21	14	0.2438	0.2439	0.993	12.9	15.5
hTAG	Cer 18:1;O2/16:0	21	10	0.0827	0.0851	0.502	12.4	10.2
DB	Cer 18:1;O2/16:0	20	15	2.4463	2.3652	0.319	11.0	8.7
YAA	Cer 18:1;O2/16:0	20	11	0.8575	0.8517	0.823	9.2	7.4
SRM	Cer 18:1;O2/18:0	20	15	0.2954	0.2801	0.244	11.4	14.4
hTAG	Cer 18:1;O2/18:0	20	11	0.0994	0.0999	0.906	10.7	12.2
DB	Cer 18:1;O2/18:0	21	15	3.8826	3.5983	0.060	12.1	11.2
YAA	Cer 18:1;O2/18:0	20	13	1.2808	1.2745	0.915	10.9	14.1
SRM	Cer 18:1;O2/24:0	21	14	0.2177	0.2135	0.702	14.2	14.9
hTAG	Cer 18:1;O2/24:0	21	11	0.0945	0.1005	0.180	11.3	12.1
DB	Cer 18:1;O2/24:0	21	15	2.4446	2.3406	0.262	12.9	9.9
YAA	Cer 18:1;O2/24:0	21	12	0.8664	0.8662	0.995	12.7	9.6

SRM	Cer 18:1;O2/24:1	20	14	0.1468	0.1424	0.590	15.4	16.4
hTAG	Cer 18:1;O2/24:1	21	13	0.0482	0.0512	0.411	15.3	22.6
DB	Cer 18:1;O2/24:1	21	14	1.7039	1.5653	0.052	14.0	10.7
YAA	Cer 18:1;O2/24:1	21	12	0.5467	0.5609	0.645	13.0	16.1

Supplementary Table 3. Inter-laboratory/platform trials measuring ceramides in NIST SRM 1950. Source data available from the publications reported in the ‘Study’ column (see main text for reference details).

Study	Year	ISTD	Extraction	Platform	Laboratories (Datasets)
Quehenberger et al. (LIPID MAPS)	2010	Cer18:1;O2/12:0	CH ₃ OH/CHCl ₃ + KOH-Hydrolysis	RP-LC/MRM	1 (1)
Bowden et al.	2017	Multiple (in-house)	Multiple (in-house)	Multiple	18 (18)
Thompson et al.	2019	Unknown	CH ₃ OH	FIA-HRMS (Biocrates p400HR)	14 (14)
Ghorasaini et al.	2021	Cer18:1;O2[d2]/16:0	(1) MTBE (2) Bligh-Dyer	FIA-IMS-MRM (Lipidyzer)	9 (9)
This study (ILS Ceramides)	2023	Cer18:1;O2[D7]/16:0 Cer18:1;O2[D7]/18:0 Cer18:1;O2[D7]/24:0 Cer18:1;O2[D7]/24:1	(1) SOP: ethyl acetate:IPA Multiple (in-house)	SOP: RP- LC/MRM Multiple	34 (39)

SUPPLEMENTARY NOTES

Supplementary Note 1. Standard Operating Protocol Harmonization Ceramides

Summary: This protocol describes the extraction and LC-MRM procedure for absolute quantification of Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/24:0 and Cer d18:1/24:1 in human plasma according to Kauhanen et al, Anal Bioanal Chem (2016) 408:3475–3483.

A calibration curve is built by injecting several dilutions of the non-labelled standards mixed with a fixed concentration of labelled standards. Each calibration point is prepared and analysed in triplicates (n=3).

To establish the endogenous concentration of the four selected ceramides in the study samples (NIST SRM1950, NIST high TAG, NIST T1D, and NIST young AA) each sample is extracted and analyzed in six replicates (n=6).

Prepare the pooled plasma quality control sample (pooled plasma QC) by mixing 100 µL each of NIST SRM1950, NIST high TAG, NIST T1D, and NIST young AA (to obtain in total 400 µL of pooled plasma).

We suggest proceeding first to measure the ceramides concentration in the four study samples and then continue with the intra-assay validation to avoid wasting material.

Extraction

Table 1.

Chemicals, solvents and materials
Ethyl acetate (EtAc)
2-propanol (IPA)
5% Bovine Serum Albumin (BSA)
96-well plates/tubes
Sealing foil
2 mL deep well plates/tubes/LC vials

Table 2.

Sample type			
Pooled Quality Control (QC) samples	10 µL pooled plasma QC	20 µL Labelled IS	570 µL EtAc:IPA 2:8 (v/v)
Matrix Blank (MB)	10 µL Matrix (pooled plasma QC) only	-	590 µL EtAc:IPA 2:8
Study Samples (S)	10 µL Human plasma (NIST SRM1950, high TAG, T1D, young AA)	20 µL Labelled IS	570 µL EtAc:IPA 2:8
Total Blank (TB)	10 µL 5% BSA	-	590 µL EtAc:IPA 2:8
Calibration line standards (STD)	10 µL 5% BSA + 20 µL non-labelled STDx mixture (Table 5)	20 µL Labelled IS	550 µL EtAc:IPA 2:8

Table 3. **Labelled internal standard** mixture solution (provided). Keep at -20° C. Equilibrate at RT and sonicate 10 min before use.

Labelled internal standard mixture in EtAc:IPA 2:8 (v/v)	Concentration, pmol/µL [µM]	Vendor
D7-Cer d18:1/16:0	0.125	Avanti Polar Lipids
D7-Cer d18:1/18:0	0.050	Avanti Polar Lipids
D7-Cer d18:1/24:0	1.500	Avanti Polar Lipids
D7-Cer d18:1/24:1	0.500	Avanti Polar Lipids

Table 4. **STD1** mixture solution (provided)

Non-labelled standards in EtAc:IPA 2:8 (v/v)		Concentration [pmol/ μ L]	Vendor
Non-labelled standards mixture	Cer d18:1/16:0	2	Avanti Polar Lipids
	Cer d18:1/18:0	2	Avanti Polar Lipids
	Cer d18:1/24:0	20	Avanti Polar Lipids
	Cer d18:1/24:1	20	Avanti Polar Lipids

Table 5. Serial dilutions of STD1 non-labelled standards **for calibration line**.

Add 20 μ L of		STD1	STD2	STD3	STD4	STD5	STD6	pmol/ μ L
Non-labelled STD mixture	Cer d18:1/16:0	2.00	1.00	0.10	0.02	0.01	0.008	
	Cer d18:1/18:0	2.00	1.00	0.10	0.02	0.01	0.008	
	Cer d18:1/24:0	20.00	10.00	1	0.20	0.1	0.08	
	Cer d18:1/24:1	20.00	10.00	1	0.20	0.1	0.08	

Extraction procedure:

- 1) Prepare different dilutions of STD1 by diluting the provided mixture (table 4) with EtAc:IPA 2:8 as suggested in Table 5.
- 2) Thaw plasma samples on ice (+4°C) and bring them to room temperature prior to extraction. Mix by pipetting up and down several times before use.
- 3) Prepare samples in plates/tubes manually or with a robotic liquid handler, according to specifications in Column 2 of Table 2.
- 4) Add 20 μ L of labelled internal standard mixture to samples (Column 3 Table 2).
- 5) For the calibration line, add 20 μ L of different dilutions of the non-labelled mixture (STD1-6).
- 6) Add 590 μ L of ethyl acetate:isopropanol (2:8, vol/vol) to Total Blank and Matrix Blank; 550 μ L to calibration line (STD); 570 μ L to study samples and QCs (Column 4 Table 2)
- 7) Mix samples 10 min by automated pipetting or vortexing
- 8) Centrifuge samples for 10 min at 3000 x g at room temperature
- 9) Transfer 50 μ L of the clear supernatant to MS vials or MS plates, close/seal, store samples at -20°C prior to LC-MRM analysis.

LC-MRM

Table 6.

Chemicals and solvents
Ammonium acetate
Formic acid
Ultra-pure water
Acetonitrile

Table 7.

LC-MS details	Specifications
Mass spectrometry	QQQ
LC	UPLC
Injection volume (indicative)	5 μ L
Weak wash	Water
Strong wash	Acetonitrile
Pre-column	Waters Acquity BEH C18, 1.7 μ m VanGuard Pre-Column
Column	Waters Acquity BEH C18, 2.1 $\times$ 50 mm id. 1.7 μ m
Column temperature	60 $^{\circ}$ C
Mobile phase A	10 mM ammonium acetate in water with 0.1% formic acid
Mobile phase B	10 mM ammonium acetate in acetonitrile:2-propanol (4:3, vol/vol) with 0.1% formic acid

Table 8.

LC gradient			
Time	A%	B%	Flow (μ L/min)
0.00	15	85	500
0.50	15	85	500
1.50	0	100	500
4.00	0	100	500
4.10	15	85	500
5.00	15	85	500

Table 9 (example based on the published reference).

MS conditions (this only applies to Sciex QTRAP 6500)	
Polarity mode	Positive
Ion spray	5000 V
Curtain gas	25 psi
Source temperature	300 $^{\circ}$ C
Gas 1	50 psi
Gas 2	35 psi
DP	30 V
EP	10 V
Collision cell exit potential	20 V
Collision energy CE	40 eV

Table 10.

Mass transitions used for absolute quantification. With different systems RT and CE might be different.					
Analyte	Mass transitions (MRM)	IS	Mass transitions (MRM)	RT (min)	CE (not applicable to different instruments)
Cer d18:1/16:0	538.5 – 264.3 $C_{34}H_{68}NO_3 - C_{18}H_{34}N$	D7- Cer d18:1/16:0	545.6 - 271.3	1.9-2.0	40
Cer d18:1/18:0	566.6 – 264.3 $C_{36}H_{72}NO_3 - C_{18}H_{34}N$	D7- Cer d18:1/18:0	573.6 – 271.3	2.1-2.2	40
Cer d18:1/24:0	650.6 – 264.3 $C_{42}H_{84}NO_3 - C_{18}H_{34}N$	D7- Cer d18:1/24:0	657.7 – 271.3	2.4-2.5	40
Cer d18:1/24:1	648.6 – 264.3 $C_{42}H_{82}NO_3 - C_{18}H_{34}N$	D7- Cer d18:1/24:1	655.7 – 271.3	2.3-2.4	40

Suggested sample sequence. Samples and QC for intra-assay validation can be measured in one single batch

Total Blank 1
Matrix blank
Calibration line 1 from STD6 to 1 (n=3)
[...]
Pooled QC
Pooled QC
SRM 1950-1
SRM 1950-2
SRM 1950-3
SRM 1950-4
SRM 1950-5
SRM 1950-6
Pooled QC
Pooled QC
T1D-1
T1D-2
T1D-3
T1D-4
T1D-5
T1D-6
Total Blank 2
Pooled QC
Pooled QC
Young AA-1
Young AA-2
Young AA-3
Young AA-4
Young AA-5
Young AA-6
Pooled QC
Pooled QC
highTAG-1

highTAG-2
highTAG-3
highTAG-4
highTAG-5
highTAG-6
Pooled QC
Pooled QC
Calibration line 2 from STD1 to 6 (n=3)
LLQC 1
LLQC 2
LLQC 3
LLQC 4
LLQC 5
LLQC 6
LQC 1
LQC 2
LQC 3
LQC 4
LQC 5
LQC 6
MQC 1
MQC 2
MQC 3
MQC 4
MQC 5
MQC 6
HQC 1
HQC 2
HQC 3
HQC 4
HQC 5
HQC 6
HLQC 1
HLQC 2
HLQC 3
HLQC 4
HLQC 5
HLQC 6
Matrix blank
Total Blank 3

Clarifications: In the corresponding Excel table we have 3 cells for each STD concentration (1-6), so we mean that we inject only once from each vial (each vial is a replicate that you prepared). The calibration curves are 2: one at the beginning and one at the end. Then for the study samples we ask to prepare 6 replicates. Then in the Excel we have 3 cells for each sample, which means this time that each vial is injected 3 times.

Table 11.

Data processing	
Processing software	(Add here name and version of the software used)

Quality controls for intra-assay variation

Prepare the pooled plasma QC sample containing equal volumes of the four NIST reference plasma you received.

The pooled QC representing middle quality control (MQC), low QC (LQC), and lowest level of QC (LLQC) is prepared by diluting MQC (e.g. two-(1:1) and three-fold (1:2)) with water. High QC (HQC) and highest level of QC (HLQC) are prepared by adding to MQC additional 10 μ L and 20 μ L respectively of STD3 endogenous standards from table 5. Internal standards are added to all QC samples.

Only intra-assay variation will be measured

The precision and accuracy of the assay is determined for each of the four ceramides measured in LLQC, LQC, MQC, HQC, and HLQC.

Intra-assay variation, precision, and accuracy is calculated for each of the ceramide in replicates of six ($n = 6$) at each QC concentration.

The intra-assay precision (percentage coefficient variance, %CV) and accuracy (percentage accuracy, %Accuracy) are calculated from the nominal concentrations according to the formulas reported in the corresponding Excel tables attached to this document.

Recovery estimation is not necessary for the published method but only for different ones. Stability estimation is not necessary for the published method but only for different ones. Calibration line is prepared in 5% BSA in water, no specific purity/type of BSA is required.

Results

Please **report the peak areas** values for Calibration lines, Samples and Intra assay QC in tables 12-15 of the corresponding Excel file.